{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 272375, "items": [{"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T18:50:22Z", "timestamp": 1574275822716}, "reference-count": 17, "publisher": "Springer Science and Business Media LLC", "issue": "11", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2009, 1, 19]], "date-time": "2009-01-19T00:00:00Z", "timestamp": 1232323200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2009, 6]]}, "DOI": "10.1038/bmt.2008.400", "type": "journal-article", "created": {"date-parts": [[2009, 1, 19]], "date-time": "2009-01-19T11:49:32Z", "timestamp": 1232365772000}, "page": "839-843", "source": "Crossref", "is-referenced-by-count": 55, "title": ["Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome"], "prefix": "10.1038", "volume": "43", "author": [{"given": "L", "family": "De Padua Silva", "sequence": "first", "affiliation": []}, {"given": "M", "family": "de Lima", "sequence": "additional", "affiliation": []}, {"given": "H", "family": "Kantarjian", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Faderl", "sequence": "additional", "affiliation": []}, {"given": "P", "family": "Kebriaei", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Giralt", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "Davisson", "sequence": "additional", "affiliation": []}, {"given": "G", "family": "Garcia-Manero", "sequence": "additional", "affiliation": []}, {"given": "R", "family": "Champlin", "sequence": "additional", "affiliation": []}, {"given": "J-P", "family": "Issa", "sequence": "additional", "affiliation": []}, {"given": "F", "family": "Ravandi", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2009, 1, 19]]}, "reference": [{"issue": "1", "key": "BFbmt2008400_CR1", "doi-asserted-by": "publisher", "first-page": "205", "DOI": "10.1182/asheducation-2006.1.205", "volume": "2006", "author": "C. A. Schiffer", "year": "2006", "unstructured": "Schiffer CA . Clinical issues in the management of patients with myelodysplasia. In: Gerwitz AM, Winter JN, Zuckerman K (eds). Hematology, Am Soc Hematol Educ Program, 2006, pp 205\u2013210.", "journal-title": "Hematology"}, {"key": "BFbmt2008400_CR2", "doi-asserted-by": "publisher", "first-page": "2429", "DOI": "10.1200/JCO.2002.04.117", "volume": "20", "author": "LR Silverman", "year": "2002", "unstructured": "Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429\u20132440.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt2008400_CR3", "doi-asserted-by": "publisher", "first-page": "1794", "DOI": "10.1002/cncr.21792", "volume": "106", "author": "H Kantarjian", "year": "2006", "unstructured": "Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794\u20131803.", "journal-title": "Cancer"}, {"key": "BFbmt2008400_CR4", "doi-asserted-by": "publisher", "first-page": "1456", "DOI": "10.1056/NEJMoa061292", "volume": "355", "author": "A List", "year": "2006", "unstructured": "List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456\u20131465.", "journal-title": "N Engl J Med"}, {"key": "BFbmt2008400_CR5", "doi-asserted-by": "publisher", "first-page": "2042", "DOI": "10.1056/NEJMra023075", "volume": "349", "author": "JG Herman", "year": "2003", "unstructured": "Herman JG, Baylin SB . Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042\u20132054.", "journal-title": "N Engl J Med"}, {"key": "BFbmt2008400_CR6", "doi-asserted-by": "publisher", "first-page": "988", "DOI": "10.1038/nrc1507", "volume": "4", "author": "JP Issa", "year": "2004", "unstructured": "Issa JP . CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988\u2013993.", "journal-title": "Nat Rev Cancer"}, {"key": "BFbmt2008400_CR7", "doi-asserted-by": "publisher", "first-page": "24", "DOI": "10.1038/ncponc0355", "volume": "2", "author": "JP Issa", "year": "2005", "unstructured": "Issa JP . Optimizing therapy with methylation inhibitors in myelodysplastic syndromes:dose, duration, and patient selection. Nat Clin Pract Oncol 2005; 2: 24\u201329.", "journal-title": "Nat Clin Pract Oncol"}, {"key": "BFbmt2008400_CR8", "doi-asserted-by": "publisher", "first-page": "2823", "DOI": "10.1182/blood.V97.9.2823", "volume": "97", "author": "M Toyota", "year": "2001", "unstructured": "Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP . Methylation profiling in acute myeloid leukemia. Blood 2001; 97: 2823\u20132829.", "journal-title": "Blood"}, {"key": "BFbmt2008400_CR9", "first-page": "51", "volume": "7", "author": "A Pinto", "year": "1993", "unstructured": "Pinto A, Zagonel V . 5-Aza-2\u2032-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993; 7: 51\u201360.", "journal-title": "Leukemia"}, {"key": "BFbmt2008400_CR10", "doi-asserted-by": "publisher", "first-page": "867", "DOI": "10.1016/S0140-6736(84)90900-0", "volume": "2", "author": "A Pinto", "year": "1984", "unstructured": "Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R . Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2\u2032-deoxycytidine. Lancet 1984; 2: 867\u2013868.", "journal-title": "Lancet"}, {"key": "BFbmt2008400_CR11", "first-page": "28", "volume": "4", "author": "A Pinto", "year": "1989", "unstructured": "Pinto A, Zagonel V, Attadia V, Bullian PL, Gattei V, Carbone A et al. 5-Aza-2\u2032-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 1989; 4: 28\u201332.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2008400_CR12", "doi-asserted-by": "publisher", "first-page": "52", "DOI": "10.1182/blood-2006-05-021162", "volume": "109", "author": "H Kantarjian", "year": "2007", "unstructured": "Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52\u201357.", "journal-title": "Blood"}, {"key": "BFbmt2008400_CR13", "author": "SH Swerdlow", "year": "2008", "unstructured": "Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Atein H et al. (eds). World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer (IARC), 2008, 439pp.", "volume-title": "World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues"}, {"key": "BFbmt2008400_CR14", "doi-asserted-by": "publisher", "first-page": "579", "DOI": "10.1182/blood-2004-01-0338", "volume": "104", "author": "CS Cutler", "year": "2004", "unstructured": "Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplasia syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579\u2013585.", "journal-title": "Blood"}, {"key": "BFbmt2008400_CR15", "first-page": "5", "volume": "29", "author": "A Ambs", "year": "2008", "unstructured": "Ambs A, Warren JL, Bellizzi KM, Topor M, Haffer SC, Clauser SB . Overview of the SEER\u2014medicare health outcomes survey linked dataset. Health Care Financ Rev 2008 Summer; 29: 5\u201321.", "journal-title": "Health Care Financ Rev"}, {"key": "BFbmt2008400_CR16", "doi-asserted-by": "publisher", "first-page": "620", "DOI": "10.1046/j.1365-2141.2000.02200.x", "volume": "110", "author": "T de Witte", "year": "2000", "unstructured": "de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 620\u2013630.", "journal-title": "Br J Haematol"}, {"key": "BFbmt2008400_CR17", "doi-asserted-by": "publisher", "first-page": "2912", "DOI": "10.1182/blood-2005-05-2004", "volume": "106", "author": "ML Sorror", "year": "2005", "unstructured": "Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidities index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912\u20132919.", "journal-title": "Blood"}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bmt2008400.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt2008400", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt2008400.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 14]], "date-time": "2019-05-14T16:04:49Z", "timestamp": 1557849889000}, "score": 65.38645, "issued": {"date-parts": [[2009, 1, 19]]}, "references-count": 17, "journal-issue": {"published-print": {"date-parts": [[2009, 6]]}, "issue": "11"}, "alternative-id": ["BFbmt2008400"], "URL": "http://dx.doi.org/10.1038/bmt.2008.400", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T06:57:58Z", "timestamp": 1575529078927}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "11", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2006, 11, 16]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Background: Relapse is the most frequent cause of treatment failure after allo-SCT in patients (pts) with AML or MDS. Median time to relapse after reduced-intensity allo-SCT is 3\u20135 months, indicating that if post-transplant interventions are to be proposed, they have to be implemented early. 5-AC is a DNA hypomethylating agent that may induce leukemic cell differentiation and increased immunogenicity, therefore potentially increasing the graft-versus-leukemia effect. Furthermore, lower doses are likely to be better tolerated after allo-SCT and to be as effective as larger doses in inducing hypomethylation. We hypothesized that 5-AC after allo-SCT will result in lower relapse rates, and designed a phase I clinical trial to determine the safest dose and schedule combination of 5-AC used as maintenance therapy after allo-SCT in pts with AML or MDS.</jats:p>\n               <jats:p>Methods: Pts with AML or high-risk MDS not in first remission are eligible. Donors are HLA-compatible related or unrelated. Conditioning regimen is gemtuzumab ozogamicin 2 mg/m2 (day -12), fludarabine, and melphalan 140 mg/m2. GVHD prophylaxis is tacrolimus and mini-methotrexate. ATG is administered to recipients of unrelated donor transplants. Three doses of 5-AC are to be studied: 8, 16, and 24 mg/m2 daily \u00d7 5 starting on day 42 post transplant. Four schedules consisting of 1, 2, 3 or 4 28-day courses of 5-AC are being explored for a total of 3\u00d74 = 12 dose-schedule combinations. The continual reassessment method with toxicity probabilities is used to determine the safest dose schedule combination.</jats:p>\n               <jats:p>Results: Twelve pts were evaluable. Median age was 55.5 years (range 25\u201366). Eight pts had AML and 4 had MDS. At the time of the transplant 4 pts were in remission and 8 had refractory disease. Donors were HLA compatible related (n=7) and unrelated (n=5). Based on the Bayesian model, 3 pts (25 %) were assigned to 8 mg/m2 \u00d7 1 cycle, 2 pts (16%) to 8 mg/m2\u00d7 2 cycles, 2 (16%) to 8 mg/m2\u00d7 3 cycles and 3 to 16 mg/m2\u00d73 cycles. All evaluable pts have received the assigned 5AC doses, and there has been no major drug-related toxicity (at 8 or 16 mg/m2). Two pts died before receiving 5-AC due to bleeding (n=1, in CR) and bacterial sepsis (n=1) post allo-SCT. With a median follow up of 5 months (2\u20139) after allo-SCT, none of the pts has relapsed and no drug related induction of GVHD has been observed. All pts were 100% donor chimeras at start of 5AC. To assess the DNA hypomethylating effect of 5-AC, the methylation status of long interspersed nuclear elements (LINE) was analyzed by pyrosequencing and used as a surrogate marker of global DNA methylation in mononuclear cells of 7 patients that have completed 1 cycle at the dose of 8 mg/m2. Mean LINE methylation pretreatment was 64.9%(\u00b15), while it was 60.7%(\u00b12.5) by day 5 (p=0.06) (last day of 5-AC administration), returning to baseline by day 1 of the next cycle. Analysis of gene specific methylation is ongoing.</jats:p>\n               <jats:p>Conclusions: At the dose of 8 mg/m2 5AC is well tolerated and may produce detectable levels of hypomethylation. It is unknown if this effect will translate in reduced relapse rate or if higher doses will be as well tolerated.</jats:p>", "DOI": "10.1182/blood.v108.11.3668.3668", "type": "journal-article", "created": {"date-parts": [[2019, 10, 11]], "date-time": "2019-10-11T12:33:25Z", "timestamp": 1570797205000}, "page": "3668-3668", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study."], "prefix": "10.1182", "volume": "108", "author": [{"given": "Andres O.", "family": "Soriano", "sequence": "first", "affiliation": [{"name": "Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA"}]}, {"given": "Richard", "family": "Champlin", "sequence": "additional", "affiliation": [{"name": "Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX, USA"}]}, {"given": "Gloria", "family": "McCormick", "sequence": "additional", "affiliation": [{"name": "Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX, USA"}]}, {"given": "Sergio", "family": "Giralt", "sequence": "additional", "affiliation": [{"name": "Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX, USA"}]}, {"given": "Peter", "family": "Thall", "sequence": "additional", "affiliation": [{"name": "Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX, USA"}]}, {"given": "Krishna", "family": "Komanduri", "sequence": "additional", "affiliation": [{"name": "Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX, USA"}]}, {"given": "Muzaffar", "family": "Qazilbash", "sequence": "additional", "affiliation": [{"name": "Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX, USA"}]}, {"given": "Guillermo", "family": "Garcia-Manero", "sequence": "additional", "affiliation": [{"name": "Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA"}]}, {"given": "Marcos", "family": "De Lima", "sequence": "additional", "affiliation": [{"name": "Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX, USA"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/108/11/3668/126894/Maintenance-Therapy-with-5Azacytidine-5AC-after", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/108/11/3668/126894/Maintenance-Therapy-with-5Azacytidine-5AC-after", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T01:17:01Z", "timestamp": 1574039821000}, "score": 33.58155, "issued": {"date-parts": [[2006, 11, 16]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2006, 11, 16]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1182/blood.v108.11.3668.3668", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T12:19:42Z", "timestamp": 1575548382950}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "Supplement_1", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2019, 11, 13]]}, "abstract": "<jats:p>Background</jats:p>\n               <jats:p>Myelodysplastic syndrome (MDS) patients who are refractory to hypomethylating agents (HMAs) have a poor prognosis with median survival &lt;6 months and few treatment options. A precision medicine approach is appealing in MDS given the biologic heterogeneity associated with the large variety of cytogenetic abnormalities and somatic mutations. We sought to determine whether a precision medicine approach combining molecular testing, ex vivo drug sensitivity screening (DSS), and in silico computational biology modeling (CBM) could be performed within an actionable timeframe (\u226430 days) to allow for personalized treatment recommendations for patients with HMA-refractory MDS.</jats:p>\n               <jats:p>Methods</jats:p>\n               <jats:p>Study design: We performed a prospective feasibility study in 21 patients with HMA-refractory MDS enrolled at Stanford University from April 2018 through March 2019. All patients had a baseline bone marrow (BM) biopsy with BM aspirate and peripheral blood (PB) samples sent for mutation testing (596-gene panel, Tempus, Chicago, IL) and ex vivo DSS (Notable Labs, Foster City, CA).</jats:p>\n               <jats:p>Ex vivo DSS: BM aspirate and PB specimens were RBC-lysed and re-suspended in serum-free media with cytokines. Samples were plated in 384-well microtiter plates and screened against FDA-approved and investigational drugs (up to 76) and drug combinations in triplicate. Specimens were treated for 72 hours and assayed using high-throughput, multi-parametic flow cytometry for cytotoxicity and differentiation (Blood 2016;128:5206).</jats:p>\n               <jats:p>In silico CBM: Genomic data were input into a computational biology model (Cell Works Group, San Jose, CA) to generate protein network maps for each patient. Mathematical modeling of MDS cell proliferation or inhibition was simulated for each patient and used to calculate drug efficacy scores for numerous agents (Leuk Res 2017;52:1-7).</jats:p>\n               <jats:p>Study endpoints: Once the gene panel, ex vivo DSS, and in silico CBM results were available, we (M.A.S., A.A., J.Z., P.L.G.) met for a molecular tumor board (MTB) to review the data and provide personalized treatment recommendations for each patient. The primary endpoint was the feasibility of providing personalized recommendations within an actionable timeframe (\u226430 days). Secondary endpoints included concordance between the ex vivo and in silico assays and the accuracy of our MTB recommendations in predicting clinical responses in vivo.</jats:p>\n               <jats:p>Results</jats:p>\n               <jats:p>The median age of the patients was 76 years (range 55-87) and 71% were male. Seventeen patients had MDS, 3 had an MDS/MPN disorder, and 1 patient had progressed to AML. 76% had higher risk disease by IPSS-R, 57% had excess blasts, and 52% had adverse cytogenetics or mutations. Patients had a median of 2 pathogenic mutations (range 0-6) with the most common including TET2, ASXL1, STAG2, DNMT3A, RUNX1, and SRSF2.</jats:p>\n               <jats:p>The median turnaround time for results of the gene panel, ex vivo DSS, and in silico CBM were 14.5, 15, and 20 days, respectively. The median turnaround time to our MTB was 27 days (range 20-32 days). MTB recommendations varied widely among patients and encompassed various drug classes including targeted therapies (venetoclax, sorafenib, lenalidomide, ruxolitinib, midostaurin, everolimus), cytotoxic agents (cytarabine, fludarabine), differentiative agents (calcitriol, ATRA), HMAs, and androgens (danazol) as single agents or in combination. The ex vivo and in silico assays were highly concordant, particularly in predicting sensitivity to HMAs and venetoclax.</jats:p>\n               <jats:p>Eight patients received treatment per our MTB recommendations. Of these 8 patients, 6 (75%) responded to the recommended therapy and 2 (25%) had stable disease. Two responding patients were bridged to allogeneic hematopoietic cell transplantation (HCT). The remaining patients elected for best supportive care (N=5), hospice (N=3), other approved therapies (N=3), a clinical trial (N=1), or allogeneic HCT without bridging therapy (N=1).</jats:p>\n               <jats:p>Conclusions</jats:p>\n               <jats:p>We demonstrate the feasibility of a novel precision medicine approach for HMA-refractory MDS patients combining mutation data, ex vivo DSS, and in silico CBM to guide clinical therapeutic decisions within an actionable timeframe. Personalized treatment recommendations accurately predicted clinical responses in vivo and enabled some patients to be bridged to allogeneic HCT. Randomized prospective trials are needed to determine whether this approach may improve outcomes for patients with HMA-refractory MDS.</jats:p>\n               <jats:sec>\n                  <jats:title>Disclosures</jats:title>\n                  <jats:p>Aleshin: Notable Labs: Consultancy. Santaguida:Notable Labs: Employment. Schaffert:Notable Labs: Employment. Abbasi:Cell Works Group, Inc.: Employment. Patterson:Notable Labs: Employment. Heiser:Notable Labs: Employment. Greenberg:Notable Labs: Research Funding; Celgene: Research Funding; Genentech: Research Funding; H3 Biotech: Research Funding; Aprea: Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood-2019-129473", "type": "journal-article", "created": {"date-parts": [[2019, 11, 14]], "date-time": "2019-11-14T10:19:12Z", "timestamp": 1573726752000}, "page": "4239-4239", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents"], "prefix": "10.1182", "volume": "134", "author": [{"given": "Michael A", "family": "Spinner", "sequence": "first", "affiliation": [{"name": "Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA"}]}, {"given": "Alexey", "family": "Aleshin", "sequence": "additional", "affiliation": [{"name": "Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA"}]}, {"given": "Marianne A", "family": "Santaguida", "sequence": "additional", "affiliation": [{"name": "Notable Labs, Foster City, CA"}]}, {"given": "Steven A", "family": "Schaffert", "sequence": "additional", "affiliation": [{"name": "Notable Labs, Foster City, CA"}]}, {"given": "Taher", "family": "Abbasi", "sequence": "additional", "affiliation": [{"name": "Cell Works Group Inc., San Jose, CA"}]}, {"given": "Jeffrey N", "family": "Sanders", "sequence": "additional", "affiliation": [{"name": "Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA"}]}, {"given": "A Scott", "family": "Patterson", "sequence": "additional", "affiliation": [{"name": "Notable Labs, Foster City, CA"}]}, {"given": "Diane", "family": "Heiser", "sequence": "additional", "affiliation": [{"name": "Notable Labs, Foster City, CA"}]}, {"given": "James L", "family": "Zehnder", "sequence": "additional", "affiliation": [{"name": "Department of Pathology, Stanford University, Palo Alto, CA"}]}, {"given": "Peter L", "family": "Greenberg", "sequence": "additional", "affiliation": [{"name": "Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/134/Supplement_1/4239/425706/A-Feasibility-Study-of-Biologically-Focused", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/134/Supplement_1/4239/425706/A-Feasibility-Study-of-Biologically-Focused", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 16]], "date-time": "2019-11-16T10:01:34Z", "timestamp": 1573898494000}, "score": 29.38471, "issued": {"date-parts": [[2019, 11, 13]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2019, 11, 13]]}, "issue": "Supplement_1"}, "URL": "http://dx.doi.org/10.1182/blood-2019-129473", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T19:32:43Z", "timestamp": 1574451163657}, "reference-count": 36, "publisher": "Wiley", "issue": "23", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1860, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer"], "published-print": {"date-parts": [[2010, 12, 1]]}, "DOI": "10.1002/cncr.25500", "type": "journal-article", "created": {"date-parts": [[2010, 7, 29]], "date-time": "2010-07-29T14:57:14Z", "timestamp": 1280415434000}, "page": "5420-5431", "source": "Crossref", "is-referenced-by-count": 266, "title": ["Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome"], "prefix": "10.1002", "volume": "116", "author": [{"given": "Marcos", "family": "de Lima", "sequence": "first", "affiliation": []}, {"given": "Sergio", "family": "Giralt", "sequence": "additional", "affiliation": []}, {"given": "Peter F.", "family": "Thall", "sequence": "additional", "affiliation": []}, {"given": "Leandro", "family": "de Padua Silva", "sequence": "additional", "affiliation": []}, {"given": "Roy B.", "family": "Jones", "sequence": "additional", "affiliation": []}, {"given": "Krishna", "family": "Komanduri", "sequence": "additional", "affiliation": []}, {"given": "Thomas M.", "family": "Braun", "sequence": "additional", "affiliation": []}, {"given": "Hoang Q.", "family": "Nguyen", "sequence": "additional", "affiliation": []}, {"given": "Richard", "family": "Champlin", "sequence": "additional", "affiliation": []}, {"given": "Guillermo", "family": "Garcia-Manero", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2010, 7, 29]]}, "reference": [{"key": "10.1002/cncr.25500-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "1431", "DOI": "10.1016/j.bbmt.2009.07.008", "article-title": "Quantifying the survival benefit for allogeneic stem cell transplant in relapsed acute myeloid leukemia", "volume": "15", "author": "Armistead", "year": "2009", "journal-title": "Biol Blood Marrow Transplant."}, {"key": "10.1002/cncr.25500-BIB2|cit2", "first-page": "511", "article-title": "One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation", "volume": "49", "author": "Thomas", "year": "1977", "journal-title": "Blood."}, {"key": "10.1002/cncr.25500-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "223", "DOI": "10.1016/S1470-2045(09)70003-8", "article-title": "Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study", "volume": "10", "author": "Fenaux", "year": "2009", "journal-title": "Lancet Oncol."}, {"key": "10.1002/cncr.25500-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "1635", "DOI": "10.1182/blood-2003-03-0687", "article-title": "Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies", "volume": "103", "author": "Issa", "year": "2004", "journal-title": "Blood."}, {"key": "10.1002/cncr.25500-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "1242", "DOI": "10.1002/cncr.11184", "article-title": "Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias", "volume": "97", "author": "de Lima", "year": "2003", "journal-title": "Cancer."}, {"key": "10.1002/cncr.25500-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "867", "DOI": "10.1016/S0140-6736(84)90900-0", "article-title": "Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2\u2032-deoxycytidine", "volume": "2", "author": "Pinto", "year": "1984", "journal-title": "Lancet."}, {"key": "10.1002/cncr.25500-BIB7|cit7", "first-page": "922", "article-title": "5-Aza-2\u2032-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias", "volume": "64", "author": "Pinto", "year": "1984", "journal-title": "Blood."}, {"key": "10.1002/cncr.25500-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "2900", "DOI": "10.1158/0008-5472.CAN-06-2986", "article-title": "5-AZA-2\u2032-deoxycytidine in cancer immunotherapy: a mouse to man story", "volume": "67", "author": "Coral", "year": "2007", "journal-title": "Cancer Res."}, {"key": "10.1002/cncr.25500-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "465", "DOI": "10.1080/08880010701558188", "article-title": "Decitabine and sickle cell disease: molecular therapy for a molecular disease", "volume": "24", "author": "Saunthararajah", "year": "2007", "journal-title": "Pediatr Hematol Oncol."}, {"key": "10.1002/cncr.25500-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "1899", "DOI": "10.1002/cncr.24198", "article-title": "Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia", "volume": "115", "author": "Jabbour", "year": "2009", "journal-title": "Cancer."}, {"key": "10.1002/cncr.25500-BIB11|cit11", "first-page": "2079", "article-title": "International scoring system for evaluating prognosis in myelodysplastic syndromes", "volume": "89", "author": "Greenberg", "year": "1997", "journal-title": "Blood."}, {"key": "10.1002/cncr.25500-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "2884", "DOI": "10.1182/blood-2009-05-223172", "article-title": "Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease", "volume": "114", "author": "Parmar", "year": "2009", "journal-title": "Blood."}, {"key": "10.1002/cncr.25500-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "258", "DOI": "10.1038/sj.leu.2405014", "article-title": "Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome", "volume": "22", "author": "de Lima", "year": "2008", "journal-title": "Leukemia."}, {"key": "10.1002/cncr.25500-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "2303", "DOI": "10.1182/blood-2007-03-078576", "article-title": "Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome", "volume": "110", "author": "Soriano", "year": "2007", "journal-title": "Blood."}, {"key": "10.1002/cncr.25500-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "113", "DOI": "10.1177/1740774507076934", "article-title": "Simultaneously optimizing dose and schedule of a new cytotoxic agent", "volume": "4", "author": "Braun", "year": "2007", "journal-title": "Clin Trials."}, {"key": "10.1002/cncr.25500-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "33", "DOI": "10.2307/2531628", "article-title": "Continual reassessment method: a practical design for phase I clinical trials in cancer", "volume": "46", "author": "O'Quigley", "year": "1990", "journal-title": "Biometrics."}, {"key": "10.1002/cncr.25500-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "457", "DOI": "10.2307/2281868", "article-title": "Nonparametric estimator from incomplete observations", "volume": "53", "author": "Kaplan", "year": "1958", "journal-title": "J Am Statistical Assoc."}, {"key": "10.1002/cncr.25500-BIB18|cit18", "author": "Mantel", "first-page": "50:163", "year": "1966", "article-title": "Evaluation of survival data and 2 new rank order statistics arising in its consideration", "journal-title": "Cancer Chemother Rep."}, {"key": "10.1002/cncr.25500-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "2361", "DOI": "10.1214/009053604000000616", "article-title": "A Bayesian X2 test for goodness-of-fit", "volume": "32", "author": "Johnson", "year": "2004", "journal-title": "Ann Stat."}, {"key": "10.1002/cncr.25500-BIB20|cit20", "year": "2009", "volume-title": "WinBugs. WinBugs Version 1.4"}, {"key": "10.1002/cncr.25500-BIB21|cit21", "author": "Venables", "year": "2002", "volume-title": "Modern Applied Statistics With Splus", "DOI": "10.1007/978-0-387-21706-2", "doi-asserted-by": "crossref"}, {"key": "10.1002/cncr.25500-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "2540", "DOI": "10.1038/sj.leu.2404828", "article-title": "Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation", "volume": "21", "author": "Oran", "year": "2007", "journal-title": "Leukemia."}, {"key": "10.1002/cncr.25500-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "112", "DOI": "10.1097/MOH.0b013e3283257a87", "article-title": "Second hematopoietic stem cell transplantation in myeloid malignancies", "volume": "16", "author": "Arfons", "year": "2009", "journal-title": "Curr Opin Hematol."}, {"key": "10.1002/cncr.25500-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "495", "DOI": "10.1038/sj.bmt.1705888", "article-title": "Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant", "volume": "41", "author": "Shaw", "year": "2008", "journal-title": "Bone Marrow Transplant."}, {"key": "10.1002/cncr.25500-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "1160", "DOI": "10.1016/j.bbmt.2007.06.007", "article-title": "Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation", "volume": "13", "author": "Mielcarek", "year": "2007", "journal-title": "Biol Blood Marrow Transplant."}, {"key": "10.1002/cncr.25500-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "50", "DOI": "10.1200/JCO.1989.7.1.50", "article-title": "Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy", "volume": "7", "author": "Mortimer", "year": "1989", "journal-title": "J Clin Oncol."}, {"key": "10.1002/cncr.25500-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "627", "DOI": "10.1038/bmt.2009.222", "article-title": "Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting", "volume": "45", "author": "Lubbert", "year": "2010", "journal-title": "Bone Marrow Transplant."}, {"key": "10.1002/cncr.25500-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "3448", "DOI": "10.1182/blood-2009-01-200519", "article-title": "MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation", "volume": "114", "author": "Figueroa", "year": "2009", "journal-title": "Blood."}, {"key": "10.1002/cncr.25500-BIB29|cit29", "first-page": "600a", "article-title": "Epigenetic manipulation of cancer testis antigen (CTAg) expression: a strategy for manipulating the graft-versus leukaemia response in patients allografted for haematological malignancies [abstract]", "volume": "112", "author": "Stankovic", "year": "2008", "journal-title": "Blood."}, {"key": "10.1002/cncr.25500-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "5869", "DOI": "10.1038/onc.2008.273", "article-title": "HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance", "volume": "27", "author": "Campoli", "year": "2008", "journal-title": "Oncogene."}, {"key": "10.1002/cncr.25500-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "2715", "DOI": "10.1182/blood-2008-05-158956", "article-title": "Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy", "volume": "113", "author": "Hambach", "year": "2009", "journal-title": "Blood."}, {"key": "10.1002/cncr.25500-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "107", "DOI": "10.1182/blood-2009-03-210393", "article-title": "Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting", "volume": "115", "author": "Sanchez-Abarca", "year": "2010", "journal-title": "Blood."}, {"key": "10.1002/cncr.25500-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "5675", "DOI": "10.1200/JCO.2005.07.061", "article-title": "Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor-lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome", "volume": "23", "author": "Schmid", "year": "2005", "journal-title": "J Clin Oncol."}, {"key": "10.1002/cncr.25500-BIB34|cit34", "doi-asserted-by": "crossref", "first-page": "108", "DOI": "10.1016/j.bbmt.2004.10.008", "article-title": "Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation", "volume": "11", "author": "Wong", "year": "2005", "journal-title": "Biol Blood Marrow Transplant."}, {"key": "10.1002/cncr.25500-BIB35|cit35", "doi-asserted-by": "crossref", "first-page": "4325", "DOI": "10.1182/blood-2002-03-0772", "article-title": "Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)", "volume": "100", "author": "Byrd", "year": "2002", "journal-title": "Blood."}, {"key": "10.1002/cncr.25500-BIB36|cit36", "doi-asserted-by": "crossref", "first-page": "4606", "DOI": "10.1182/blood-2007-06-096966", "article-title": "Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences", "volume": "110", "author": "Sorror", "year": "2007", "journal-title": "Blood."}], "container-title": ["Cancer"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.25500", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 6, 1]], "date-time": "2019-06-01T00:36:06Z", "timestamp": 1559349366000}, "score": 27.417786, "subtitle": ["A dose and schedule finding study"], "issued": {"date-parts": [[2010, 7, 29]]}, "references-count": 36, "journal-issue": {"published-print": {"date-parts": [[2010, 12, 1]]}, "issue": "23"}, "URL": "http://dx.doi.org/10.1002/cncr.25500", "relation": {"cites": []}, "ISSN": ["0008-543X"], "issn-type": [{"value": "0008-543X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T18:28:00Z", "timestamp": 1574274480545}, "reference-count": 25, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2009, 1, 12]], "date-time": "2009-01-12T00:00:00Z", "timestamp": 1231718400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2009, 7]]}, "DOI": "10.1038/bmt.2008.423", "type": "journal-article", "created": {"date-parts": [[2009, 1, 12]], "date-time": "2009-01-12T16:49:39Z", "timestamp": 1231778979000}, "page": "13-17", "source": "Crossref", "is-referenced-by-count": 17, "title": ["Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG"], "prefix": "10.1038", "volume": "44", "author": [{"given": "M G", "family": "Martin", "sequence": "first", "affiliation": []}, {"given": "G L", "family": "Uy", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Procknow", "sequence": "additional", "affiliation": []}, {"given": "K", "family": "Stockerl-Goldstein", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Cashen", "sequence": "additional", "affiliation": []}, {"given": "P", "family": "Westervelt", "sequence": "additional", "affiliation": []}, {"given": "C N", "family": "Abboud", "sequence": "additional", "affiliation": []}, {"given": "K", "family": "Augustin", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "Luo", "sequence": "additional", "affiliation": []}, {"given": "J F", "family": "DiPersio", "sequence": "additional", "affiliation": []}, {"given": "R", "family": "Vij", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2009, 1, 12]]}, "reference": [{"key": "BFbmt2008423_CR1", "doi-asserted-by": "publisher", "first-page": "330", "DOI": "10.1111/j.1365-2141.1999.01337.x", "volume": "105", "author": "ED Thomas", "year": "1999", "unstructured": "Thomas ED . A history of haemopoietic cell transplantation. Br J Haematol 1999; 105: 330\u2013339.", "journal-title": "Br J Haematol"}, {"key": "BFbmt2008423_CR2", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/S0301-472X(02)01020-2", "volume": "31", "author": "R Storb", "year": "2003", "unstructured": "Storb R . Allogeneic hematopoietic stem cell transplantation\u2014yesterday, today and tomorrow. Exp Hematol 2003; 31: 1\u201310.", "journal-title": "Exp Hematol"}, {"key": "BFbmt2008423_CR3", "doi-asserted-by": "publisher", "first-page": "646", "DOI": "10.7326/0003-4819-120-8-199404150-00004", "volume": "120", "author": "RP Gale", "year": "1994", "unstructured": "Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120: 646\u2013652.", "journal-title": "Ann Intern Med"}, {"key": "BFbmt2008423_CR4", "first-page": "2041", "volume": "86", "author": "H-J Kolb", "year": "1995", "unstructured": "Kolb H-J, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effects of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041.", "journal-title": "Blood"}, {"key": "BFbmt2008423_CR5", "author": "N Lamanna", "first-page": "275", "year": "2008", "unstructured": "Lamanna N, von Hassel M, Weiss M . In: Estey EH, Faderl SH, Kantarjian HM (eds). Relapsed Acute Lymphoblastic Leukemia in Acute Leukemia. Springer: New York, 2008, pp 275\u2013279.", "volume-title": "Relapsed Acute Lymphoblastic Leukemia in Acute Leukemia"}, {"key": "BFbmt2008423_CR6", "first-page": "4531", "volume": "89", "author": "S Giralt", "year": "1997", "unstructured": "Giralt S, Estey E, Albitar M, van Besien K, Rond\u00f3n G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531\u20134536.", "journal-title": "Blood"}, {"key": "BFbmt2008423_CR7", "doi-asserted-by": "publisher", "first-page": "656", "DOI": "10.1038/sj.bmt.1705075", "volume": "36", "author": "AA Kassim", "year": "2005", "unstructured": "Kassim AA, Chinratanalab W, Ferrar JL, Mineishi S . Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: what is the best recipe? Bone Marrow Transplant 2005; 36: 656\u2013674.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2008423_CR8", "doi-asserted-by": "publisher", "first-page": "1810", "DOI": "10.1182/blood-2004-05-1947", "volume": "105", "author": "EP Alyea", "year": "2005", "unstructured": "Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810\u20131814.", "journal-title": "Blood"}, {"key": "BFbmt2008423_CR9", "first-page": "756", "volume": "91", "author": "S Slavin", "year": "1998", "unstructured": "Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756\u2013763.", "journal-title": "Blood"}, {"key": "BFbmt2008423_CR10", "doi-asserted-by": "publisher", "first-page": "296", "DOI": "10.1046/j.1365-2141.2003.04281.x", "volume": "121", "author": "S Mineishi", "year": "2003", "unstructured": "Mineishi S, Kanda Y, Saito T, Nakai K, Makimoto A, Kami M et al. Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with hematological malignancies. Br J Haematol 2003; 121: 296\u2013303.", "journal-title": "Br J Haematol"}, {"key": "BFbmt2008423_CR11", "first-page": "2438", "volume": "5", "author": "K Lofti", "year": "1999", "unstructured": "Lofti K, Mansson E, Spasokoukotskaja T, Pettersson B, Liliemark J, Peterson C et al. Biochemical pharmacology and resistance to 2-chloro-2\u2032-arabino-fluoro-2\u2032-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999; 5: 2438\u20132444.", "journal-title": "Clin Cancer Res"}, {"key": "BFbmt2008423_CR12", "unstructured": "Erba HP, Kantarjian HM, Claxton D, Arellano M, Lyons R, Kovacsovics T et al. Phase II study of single agent clofarabine in previously untreated older adult patients with AML unlikely to benefit from standard induction chemotherapy. ASCO 2008 Annual Meeting Abstract 7025.", "DOI": "10.1200/jco.2008.26.15_suppl.7025", "doi-asserted-by": "crossref"}, {"key": "BFbmt2008423_CR13", "doi-asserted-by": "publisher", "first-page": "2379", "DOI": "10.1182/blood-2003-03-0925", "volume": "102", "author": "HM Kantarjian", "year": "2003", "unstructured": "Kantarjian HM, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379\u20132386.", "journal-title": "Blood"}, {"key": "BFbmt2008423_CR14", "unstructured": "Faderl S, Gandhi V, O'Brien S, Giles F, Cortes J, Plunkett W et al. Clofarabine is active in myelodysplastic syndrome. Blood 2006; 108: abstract 2660."}, {"key": "BFbmt2008423_CR15", "doi-asserted-by": "publisher", "first-page": "940", "DOI": "10.1182/blood-2004-05-1933", "volume": "105", "author": "S Faderl", "year": "2005", "unstructured": "Faderl S, Ghandhi V, O'Brien S, Bonate P, Cortes J, Estey E et al. Results of a phase 1\u20132 study of clofarabine in combination with cytarabine (Ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105: 940\u2013947.", "journal-title": "Blood"}, {"key": "BFbmt2008423_CR16", "first-page": "552a", "volume": "108", "author": "E Agura", "year": "2006", "unstructured": "Agura E, Berryman B, Brougher L, Coop B, De Leon A, Fay J et al. Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsed AML and in elderly patients with untreated AML who are at high risk for anthracycline toxicity. Blood 2006; 108: 552a (abstract 1951).", "journal-title": "Blood"}, {"key": "BFbmt2008423_CR17", "unstructured": "Lang PJ, Mueller I, Teltschik H, Pfeiffer M, Ebinger M, Feuchtinger T et al. A new conditioning regimen with clofarabine for allogeneic stem cell transplantation in pediatric patients with refractory disease. Blood (ASH Annu Meet Abstr) 2007; 110: abstract 3019."}, {"key": "BFbmt2008423_CR18", "unstructured": "Agura ED, Berryman RB, Fay JW, Pineiro LA, Vance EA, Tadic-Ovcina M . Preliminary results of phase II trial of clofarabine with parenteral busulfan followed by allogeneic related or unrelated donor transplantation for the treatment of hematologic malignancies and diseases. Blood (ASH Ann Meet Abstr) 2007; 110: abstract 4954."}, {"key": "BFbmt2008423_CR19", "doi-asserted-by": "publisher", "first-page": "683", "DOI": "10.1038/sj.bmt.1703530", "volume": "29", "author": "N Kroger", "year": "2002", "unstructured": "Kroger N, Zabelina T, Kruger W, Renges H, Stute N, Rischewski J et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant 2002; 29: 683\u2013689.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2008423_CR20", "first-page": "122", "volume": "78", "author": "M Remberger", "year": "2004", "unstructured": "Remberger M, Svahn BM, Mattsson J, Ringden O . Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 2004; 78: 122\u2013127.", "journal-title": "Transplantation"}, {"key": "BFbmt2008423_CR21", "first-page": "181", "volume": "104", "author": "HJ Deeg", "year": "2004", "unstructured": "Deeg HJ, Appelbaum FR, Storer B, Cassarella M, Scott B, McDonald G et al. Reduced incidence of acute and chronic graft-versus-host disease (GvHD) without increased relapse in patients with high-risk myeloid disorders given thymoglobulin (THY) as part of the transplant conditioning regimen: a dose-finding study. Blood (ASH Annu Meet Abstr) 2004; 104: 181.", "journal-title": "Blood (ASH Annu Meet Abstr)"}, {"key": "BFbmt2008423_CR22", "unstructured": "Full prescribing information available at \n                    www.thymoglobulin.com\n                    \n                  ."}, {"key": "BFbmt2008423_CR23", "doi-asserted-by": "publisher", "first-page": "1638", "DOI": "10.1182/blood-2007-11-124602", "volume": "112", "author": "S Faderl", "year": "2008", "unstructured": "Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z et al. A randomized study of clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112: 1638\u20131645.", "journal-title": "Blood"}, {"key": "BFbmt2008423_CR24", "unstructured": "Data on file, Genzyme Oncology Cooperation."}, {"key": "BFbmt2008423_CR25", "unstructured": "www.clinicaltrials.gov\n                    \n                  , accessed 15 September, 2008."}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bmt2008423.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt2008423", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt2008423.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 3]], "date-time": "2019-05-03T20:05:31Z", "timestamp": 1556913931000}, "score": 26.444542, "issued": {"date-parts": [[2009, 1, 12]]}, "references-count": 25, "journal-issue": {"published-print": {"date-parts": [[2009, 7]]}, "issue": "1"}, "alternative-id": ["BFbmt2008423"], "URL": "http://dx.doi.org/10.1038/bmt.2008.423", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:33:05Z", "timestamp": 1575531185111}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "21", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 11, 15]]}, "abstract": "<jats:sec>\n                  <jats:title>Introduction</jats:title>\n                  <jats:p>Disease recurrence is the major cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT) for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Graft-versus-host disease (GVHD) is the major cause of non-relapse morbidity and mortality after alloHSCT. Decitabine (DAC) is a hypomethylating agent that irreversibly binds to and inhibits DNA methyltransferase-1, leading to loss of DNA methylation. DAC maintenance may help eradicate minimal residual disease and facilitate a graft-versus-leukemia effect. Lower DAC doses are expected to be better tolerated after alloHSCT and equally effective in promoting hypomethylation. Additionally, DAC maintenance may have a favorable effect on the incidence of GVHD by enhancing the effect of T-regulatory lymphocytes (Choi et al, Blood, 2012).</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>Patients (pts) with AML/MDS in complete remission (CR) after alloHSCT, with ANC&gt; 1,500/mm3, platelets&gt; 50,000/mm3, and without grade III-IV acute GVHD were eligible to receive DAC, starting between day +50 and +100 after alloHSCT. We investigated 4 DAC doses: 5, 7.5, 10 and 15 mg/m2/day IV x 5 days of a 6-week cycle, for a total of 8 cycles. Each cohort contained 4-8 evaluable patients. The Maximum Tolerated Dose (MTD) was defined as the maximum dose at which&lt; 20% of patients experience hematologic or non-hematologic dose limiting toxicities (DLT) during the 1st cycle of treatment. GVHD prophylaxis was at the physician discretion.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>19 pts were enrolled to date; the median age was 60 y (22-66); 14 pts had AML and 5 MDS. All conditioning regimens were myeloablative; 14 donors were unrelated and 5 related. 3 cohorts have been completed and a final 4th cohort is currently enrolling. Median follow-up from alloHSCT is 24 mo (7-36). 8 pts (44%) completed all 8 cycles: 7 pts remain in CR with stable counts and full donor chimerism and 1 pt developed CNS-only relapse 26 mo after alloHSCT. 9 pts went off study before cycle 6: 1 pt for poor compliance after 6 cycles, 3 pts for relapsed disease (after 1, 2 and 5 cycles, respectively), 2 pts for sepsis, and 2 pts after physician decision. 6 pts have died: 3 from relapse, 2 from sepsis after 3 cycles of DAC (they were not neutropenic at a time), and 1 form sepsis &gt;1 y after getting off study. 2 pts are still on study passed 3rd cycle. DAC maintenance was well tolerated. Associated hematological toxicities were mostly grade I/II leukopenia and thrombocytopenia. There was one occurrence of hematological DLT. No MTD has been reached. Non-hematological toxicities were grade I/II nausea, fatigue, neuropathy, and transaminase elevation. 2 pts had grade I-II acute GVHD prior to starting DAC and both resolved while on DAC; 1 pt developed grade IV gut GVHD coinciding with first cycle of DAC that completely resolved on DAC; 1 pt developed late acute GVHD of skin and liver around 6th cycle of DAC that resolved after few wks. 2/8 pts who completed 8 cycles of DAC developed very mild skin and oral chronic GVHD not requiring any systemic therapy, 1/8 pt developed late acute GVHD responding to therapy, and 1 pt developed overlap GVHD syndrome. 4/7 pts who went off study prior cycle 6, and did not have an early relapse, developed severe chronic GVHD requiring intensive immunosuppressive therapy.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion</jats:title>\n                  <jats:p>To our knowledge this is the first report of DAC as maintenance therapy after alloHSCT. DAC at the dose of 15 mg/m2 for 5 days every 6 weeks is safe and can be administered in heavily pretreated pts in the post-alloHSCT setting. Approximately 43% of pts were able to receive all 8 cycles. The lack of toxicities and low incidence of GVHD indicate that a longer period of administration should be investigated. Although there is a trend of increased FOXP3 expression, results were not statistically significant. Further correlative studies, including genome-wide methylation studies, are ongoing.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Disclosures:</jats:title>\n                  <jats:p>Off Label Use: Decitabine maintenance after alloHSCT.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v122.21.4638.4638", "type": "journal-article", "created": {"date-parts": [[2019, 10, 14]], "date-time": "2019-10-14T10:00:52Z", "timestamp": 1571047252000}, "page": "4638-4638", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Maintenance Therapy With Decitabine After Allogeneic Hematopoietic Stem Cell Transplantation For Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome"], "prefix": "10.1182", "volume": "122", "author": [{"given": "Iskra", "family": "Pusic", "sequence": "first", "affiliation": [{"name": "Oncology Division, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA,"}]}, {"given": "Jaebok", "family": "Choi", "sequence": "additional", "affiliation": [{"name": "Oncology Division, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA,"}]}, {"given": "Noel", "family": "Bernabe", "sequence": "additional", "affiliation": [{"name": "Oncology Division, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA,"}]}, {"given": "Camille N.", "family": "Abboud", "sequence": "additional", "affiliation": [{"name": "Oncology Division, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA,"}]}, {"given": "Peter", "family": "Westervelt", "sequence": "additional", "affiliation": [{"name": "Oncology Division, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA,"}]}, {"given": "Ravi", "family": "Vij", "sequence": "additional", "affiliation": [{"name": "Oncology Division, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA,"}]}, {"given": "Amanda F", "family": "Cashen", "sequence": "additional", "affiliation": [{"name": "Oncology Division, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA,"}]}, {"given": "Geoffrey L.", "family": "Uy", "sequence": "additional", "affiliation": [{"name": "Oncology Division, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA,"}]}, {"given": "Keith E.", "family": "Stockerl-Goldstein", "sequence": "additional", "affiliation": [{"name": "Oncology Division, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA,"}]}, {"given": "John F.", "family": "Dipersio", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/122/21/4638/11763/Maintenance-Therapy-With-Decitabine-After", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/122/21/4638/11763/Maintenance-Therapy-With-Decitabine-After", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 16]], "date-time": "2019-11-16T05:27:59Z", "timestamp": 1573882079000}, "score": 26.19253, "issued": {"date-parts": [[2013, 11, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2013, 11, 15]]}, "issue": "21"}, "URL": "http://dx.doi.org/10.1182/blood.v122.21.4638.4638", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T17:26:18Z", "timestamp": 1575221178315}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 5, 1]], "date-time": "2013-05-01T00:00:00Z", "timestamp": 1367366400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia Research"], "published-print": {"date-parts": [[2013, 5]]}, "DOI": "10.1016/s0145-2126(13)70224-8", "type": "journal-article", "created": {"date-parts": [[2013, 5, 9]], "date-time": "2013-05-09T07:33:21Z", "timestamp": 1368084801000}, "page": "S102", "source": "Crossref", "is-referenced-by-count": 0, "title": ["P-176 Hypomethylating therapy in the management of an old older patient with myelodysplastic syndrome followed in a home care program"], "prefix": "10.1016", "volume": "37", "author": [{"given": "P.", "family": "Niscola", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Tendas", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Palombi", "sequence": "additional", "affiliation": []}, {"given": "M.M.", "family": "Trawinska", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Cupelli", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Giovannini", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Scaramucci", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Catalano", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Perrotti", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "De Fabritiis", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Leukemia Research"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0145212613702248?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0145212613702248?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 16]], "date-time": "2018-10-16T04:28:06Z", "timestamp": 1539664086000}, "score": 26.083511, "issued": {"date-parts": [[2013, 5]]}, "references-count": 0, "alternative-id": ["S0145212613702248"], "URL": "http://dx.doi.org/10.1016/s0145-2126(13)70224-8", "ISSN": ["0145-2126"], "issn-type": [{"value": "0145-2126", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:23:32Z", "timestamp": 1575530612653}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "22", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2009, 11, 20]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Abstract 3817</jats:p>\n               <jats:p>Poster Board III-753</jats:p>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>The multi-center ADOPT trial (J Clin Oncol 2009; 27:3942) demonstrated that decitabine (Dacogen), a cytidine analog with hypomethylating and direct cytotoxic properties, when administered to MDS patients with IPSS '0.5 on an outpatient schedule of 20 mg/m2 IV infusion 5 days per month resulted in an overall improvement rate of 51%, including 32% complete responses (CR+mCR), using the International Working Group 2006 criteria. The impact of obtaining a cytogenetic response to decitabine therapy on subsequent hematological parameters or survival is the focus of this analysis.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Study Design/Methods</jats:title>\n                  <jats:p>99 patients with de novo or secondary MDS were enrolled on the ADOPT trial. 49 patients had abnormal cytogenetics at baseline. 33 patients underwent at least one successful post-treatment karyotypic analysis and were therefore evaluable for cytogenetic response. Data analysis utilized student t-tests and comparisons of proportions.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>17/33 evaluable patients (52%) achieved a cytogenetic response, with 11 complete responses and 6 partial responses (i.e., &gt;50% reduction in abnormal metaphases). Responses were noted among patients in all IPSS cytogenetic risk categories: low risk cytogenetics 3/3 (100%), intermediate risk cytogenetic 5/8 (62%), and high risk cytogenetic (43%). Cytogenetic responses by abnormality included: -Y (3/3), del 5q (1/7) 1, del 20q (1/2), complex (6/14), chromosome 7 abnormalities (6/14), +8 (5/6), and others (3/7). Baseline characteristics were similar among cytogenetic responders and non-responders: mean age 72.2 vs 68.6 years (p=0.30), males 94 vs 63% (p=0.07), secondary MDS 24 vs 13% (p=0.72), high risk IPSS 35 vs 63% (p=0.21), int-2+high risk IPSS 59 vs 85% (p=0.20), blasts &lt;10% 59 vs 31% (p=0.21), red cell transfusion dependent 41 vs 69% (p=0.21) and platelet transfusion dependent 6 vs 19% (p=0.54). The median time to cytogenetic response was 2.3 months, coinciding with the first post-treatment marrow sampling timing. Of the 17 cytogenetic responders, 13 (76%) had a clinical hematological responses (10 CR and 3 mCR) which was significantly higher (p=0.003) than the 3 of 16 evaluable patients (18%) not experiencing a cytogenetic response. Among cytogenetic responders the duration of the hematological response (451 days, 95% CI 143, NE) also was greater than the duration of hematological response among cytogenetic non-responders (219 days, 95% CI 184, NE). 71% (12/17) of cytogenetic responders were red cell transfusion independent on study by IWG criteria compared to 44% (7/16) non-cytogenetic responders (p=0.22). Significantly more cytogenetic responders achieved prolonged red cell transfusion independence lasting at least 24 weeks (10/17; 59%) compared to cytogenetic non-responders (3/16; 19%) (p=0.04). 88% (15/17) of cytogenetic responders were platelet transfusion independent during the study compared to 75% (12/16) non-cytogenetic responders (p=0.61). Higher rates of prolonged platelet transfusion independence lasting at least 24 weeks were achieved among 82% (14/17) cytogenetic responders versus only 38% (6/16) cytogenetic non-responders (p=0.03). Achieving a cytogenetic response correlated with improved survival. Cytogenetic responders had a median survival of 627 days (95% CI 420,760) versus 318 days (95% CI 265, 447) for cytogenetic non-responders.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>Outpatient administration of decitabine (20mg/m2 IV 5 days per month) resulted in cytogenetic responses in 52% of patients with MDS with baseline cytogenetic abnormalities, with a median time to response of 2.3 months. Patients achieving a cytogenetic response had higher rates of hematological responses, longer durations of transfusion independence, and a doubling of projected survival. This analysis suggests that a deeper early response documented by cytogenetics with decitabine correlates with improved long term outcomes, and supports early cytogenetic testing to predict hematological response.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Disclosures:</jats:title>\n                  <jats:p>Goldberg: Eisai, Inc.: Research Funding.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v114.22.3817.3817", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T17:09:12Z", "timestamp": 1570986552000}, "page": "3817-3817", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Myelodysplastic Syndrome Patients Obtaining a Cytogenetic Response to Outpatient Decitabine Experience Improved Hematological Responses and Longer Survival: Additional Analyses From the ADOPT Trial."], "prefix": "10.1182", "volume": "114", "author": [{"given": "Stuart L.", "family": "Goldberg", "sequence": "first", "affiliation": [{"name": "John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA,"}]}, {"given": "David P", "family": "Steensma", "sequence": "additional", "affiliation": [{"name": "Department of Hematological Malignancies, Dana Farber Cancer Institute, Boston, MA, USA"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/114/22/3817/76219/Myelodysplastic-Syndrome-Patients-Obtaining-a", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/114/22/3817/76219/Myelodysplastic-Syndrome-Patients-Obtaining-a", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 17]], "date-time": "2019-11-17T19:26:09Z", "timestamp": 1574018769000}, "score": 25.93553, "issued": {"date-parts": [[2009, 11, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2009, 11, 20]]}, "issue": "22"}, "URL": "http://dx.doi.org/10.1182/blood.v114.22.3817.3817", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T12:52:22Z", "timestamp": 1574340742190}, "publisher-location": "Berlin, Heidelberg", "reference-count": 71, "publisher": "Springer Berlin Heidelberg", "isbn-type": [{"value": "9783540223870", "type": "print"}, {"value": "9783540490081", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1007/978-3-540-49008-1_51", "type": "book-chapter", "created": {"date-parts": [[2007, 12, 31]], "date-time": "2007-12-31T05:57:19Z", "timestamp": 1199080639000}, "page": "392-400", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Carpal Tunnel Syndrome: Multicenter Studies with Multiperspective Assessment \u2014 Results of the Italian CTS Study Group"], "prefix": "10.1007", "author": [{"given": "L.", "family": "Padua", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "51_CR1", "doi-asserted-by": "crossref", "first-page": "2406", "DOI": "10.1212/WNL.43.11.2406", "volume": "43", "author": "American Academy of Neurology, American Association of Electrodiagnostic Medicine, American Academy of Physical Medicine and Rehabilitation", "year": "1993", "unstructured": "American Academy of Neurology, American Association of Electrodiagnostic Medicine, American Academy of Physical Medicine and Rehabilitation (1993) Practice parameter for carpal tunnel syndrome (summary statement). Neurology 43:2406\u20132409", "journal-title": "Neurology"}, {"key": "51_CR2", "doi-asserted-by": "crossref", "first-page": "2404", "DOI": "10.1212/WNL.43.11.2404", "volume": "43", "author": "American Academy of Neurology, American Association of Electrodiagnostic Medicine, American Academy of Physical Medicine and Rehabilitation", "year": "1993", "unstructured": "American Academy of Neurology, American Association of Electrodiagnostic Medicine, American Academy of Physical Medicine and Rehabilitation (1993) Practice parameter for electrodiagnostic studies in carpal tunnel syndrome (summary statement). Neurology 43:2404\u20132405", "journal-title": "Neurology"}, {"key": "51_CR3", "doi-asserted-by": "publisher", "first-page": "1392", "DOI": "10.1002/mus.880161220", "volume": "16", "author": "American Association of Electrodiagnostic Medicine Quality Assurance Committee", "year": "1993", "unstructured": "American Association of Electrodiagnostic Medicine Quality Assurance Committee (1993) Literature review of the usefulness of nerve conduction studies and electromyography for the evaluation of patients with carpal tunnel syndrome. Muscle Nerve 16:1392\u20131414", "journal-title": "Muscle Nerve"}, {"key": "51_CR4", "doi-asserted-by": "crossref", "first-page": "1589", "DOI": "10.1212/WNL.58.11.1589", "volume": "58", "author": "American Association of Electrodiagnostic Medicine, American Academy of Neurology, American Academy of Physical Medicine and Rehabilitation", "year": "2002", "unstructured": "American Association of Electrodiagnostic Medicine, American Academy of Neurology, American Academy of Physical Medicine and Rehabilitation (2002) Practice parameter: electrodiagnostic studies in carpal tunnel syndrome. Neurology 58:1589\u20131592", "journal-title": "Neurology"}, {"key": "51_CR5", "first-page": "249", "volume": "84", "author": "m. Qattan Al", "year": "1994", "unstructured": "Al Qattan mm, Manktelow RT, Bowen CV (1994) Pregnancy-induced carpal tunnel syndrome requiring surgical release longer than 2 years after delivery. Obstet Gynecol 84:249\u2013251", "journal-title": "Obstet Gynecol"}, {"key": "51_CR6", "doi-asserted-by": "publisher", "first-page": "153", "DOI": "10.1001/jama.282.2.153", "volume": "282", "author": "I. Atroshi", "year": "1999", "unstructured": "Atroshi I, Gummesson C, Johnsson R et al. (1999) Prevalence of carpal tunnel syndrome in general population. JAMA 282:153\u2013158", "journal-title": "JAMA"}, {"key": "51_CR7", "doi-asserted-by": "crossref", "first-page": "1046", "DOI": "10.1136/bmj.314.7086.1046", "volume": "314", "author": "A. Barker", "year": "1997", "unstructured": "Barker A, Powell R (1997) Guidelines exist on ownership of data and authorship in multicentre collaboration. BMJ 314:1046", "journal-title": "BMJ"}, {"key": "51_CR8", "doi-asserted-by": "publisher", "first-page": "1169", "DOI": "10.1093/rheumatology/33.12.1169", "volume": "33", "author": "S.J. Boniface", "year": "1994", "unstructured": "Boniface SJ, Morris I, MacLeod A (1994) How does neurophysiological assessment influence the management and outcome of patients with carpal tunnel syndrome? Br J Rheumatol 33:1169\u20131170", "journal-title": "Br J Rheumatol"}, {"key": "51_CR9", "doi-asserted-by": "crossref", "first-page": "243", "DOI": "10.1136/jnnp.34.3.243", "volume": "34", "author": "F. Buchthal", "year": "1971", "unstructured": "Buchthal F, Rosenfalck A (1971) Sensory conduction from digit to palm and from palm to wrist in the carpal tunnel syndrome. J Neurol Neurosurg Psychiatr 34:243\u2013252", "journal-title": "J Neurol Neurosurg Psychiatr"}, {"key": "51_CR10", "doi-asserted-by": "publisher", "first-page": "101", "DOI": "10.1016/0168-5597(87)90037-2", "volume": "68", "author": "G.J. Carroll", "year": "1987", "unstructured": "Carroll GJ (1987) Comparison of median and radial nerve sensory latencies in the electrophysiological diagnosis of carpal tunnel syndrome. Electroencephalogr Clin Neurophysiol 68:101\u2013106", "journal-title": "Electroencephalogr Clin Neurophysiol"}, {"key": "51_CR11", "doi-asserted-by": "publisher", "first-page": "141", "DOI": "10.1002/ana.410370202", "volume": "37", "author": "O. Devinsky", "year": "1995", "unstructured": "Devinsky O (1995) Outcome research in neurology: incorporating health-related quality of life. Ann Neurol 37:141\u2013142", "journal-title": "Ann Neurol"}, {"key": "51_CR12", "doi-asserted-by": "publisher", "first-page": "233", "DOI": "10.3109/00016348709020753", "volume": "66", "author": "G. Ekman-Ordeberg", "year": "1987", "unstructured": "Ekman-Ordeberg G, Salgeback S, Ordeberg G (1987) Carpal tunnel syndrome in pregnancy. A prospective study. Acta Obstet Gynecol Scand 66:233\u2013235", "journal-title": "Acta Obstet Gynecol Scand"}, {"key": "51_CR13", "doi-asserted-by": "publisher", "first-page": "417", "DOI": "10.1136/oem.56.6.417", "volume": "56", "author": "R.G. Gorsche", "year": "1999", "unstructured": "Gorsche RG, Wiley JP, Renger RF et al. (1999) Prevalence and incidence of carpal tunnel syndrome in a meat packing plant. Occup Environ Med 56:417\u2013422", "journal-title": "Occup Environ Med"}, {"key": "51_CR14", "first-page": "738", "volume": "72", "author": "F. Giannini", "year": "1991", "unstructured": "Giannini F, Passero S, Cioni R et al. (1991) Electrophysiologic evaluation of local steroid injection in carpal tunnel syndrome. Arch Phys Med Rehabil 72:738\u2013742", "journal-title": "Arch Phys Med Rehabil"}, {"key": "51_CR15", "doi-asserted-by": "publisher", "first-page": "71", "DOI": "10.1016/S1388-2457(01)00704-0", "volume": "113", "author": "F. Giannini", "year": "2002", "unstructured": "Giannini F, Cioni R, Mondelli M et al. (2002) A new clinical scale of carpal tunnel syndrome: validation of the measurement and clinical-neurophysiological assessment. Clin Neurophysiol 113: 71\u201377", "journal-title": "Clin Neurophysiol"}, {"key": "51_CR16", "doi-asserted-by": "publisher", "first-page": "44", "DOI": "10.1016/S0924-980X(97)00076-3", "volume": "109", "author": "P. Girlanda", "year": "1998", "unstructured": "Girlanda P, Quartarone A, Sinicropi S et al. (1998) Electrophysiological studies in mild carpal tunnel syndrome. Electroencephalogr Clin Neurophysiol 109:44\u201349", "journal-title": "Electroencephalogr Clin Neurophysiol"}, {"key": "51_CR17", "doi-asserted-by": "crossref", "first-page": "144", "DOI": "10.1097/00007611-197802000-00018", "volume": "71", "author": "J.S. Gould", "year": "1978", "unstructured": "Gould JS, Wissinger HA (1978) Carpal tunnel syndrome in pregnancy. South Med J 71:144\u2013154", "journal-title": "South Med J"}, {"key": "51_CR18", "doi-asserted-by": "crossref", "first-page": "622", "DOI": "10.7326/0003-4819-118-8-199304150-00009", "volume": "118", "author": "G.H. Guyatt", "year": "1993", "unstructured": "Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Ann Intern Med 118:622\u2013629", "journal-title": "Ann Intern Med"}, {"key": "51_CR19", "doi-asserted-by": "publisher", "first-page": "441", "DOI": "10.1097/00019052-199612000-00008", "volume": "9", "author": "J.C. Hobart", "year": "1996", "unstructured": "Hobart JC, Freeman JA, Lamping DL (1996) Physicians and patient-oriented outcomes in progressive neurological disease: which to measure? Curr Opin Neurol 9:441\u2013444", "journal-title": "Curr Opin Neurol"}, {"key": "51_CR20", "doi-asserted-by": "crossref", "first-page": "1562", "DOI": "10.2106/00004623-199310000-00017", "volume": "75-A", "author": "R.B. Keller", "year": "1993", "unstructured": "Keller RB, Rudicel SA, Liang MH (1993) Outcome Research in orthopaedics. J Bone Joint Surg 75-A:1562\u20131574", "journal-title": "J Bone Joint Surg"}, {"key": "51_CR21", "doi-asserted-by": "crossref", "first-page": "1286", "DOI": "10.2106/00004623-199072090-00002", "volume": "72", "author": "R.B. Keller", "year": "1990", "unstructured": "Keller RB, Soule DN, Wennberg JE, Hanley DF (1990) Dealing with geographic variations in the use of hospitals: the experience of the Maine Medical Assessment Foundation Orthopaedic Study Group. J Bone Joint Surg Am 72:1286\u20131293", "journal-title": "J Bone Joint Surg Am"}, {"key": "51_CR22", "first-page": "151", "volume": "25", "author": "I. Kimura", "year": "1985", "unstructured": "Kimura I, Ayyar DR (1985) The carpal tunnel syndrome: electrophysiological aspects of 639 symptomatic extremities. Electromyogr Clin Neurophysiol 25:151\u2013164", "journal-title": "Electromyogr Clin Neurophysiol"}, {"key": "51_CR23", "doi-asserted-by": "crossref", "first-page": "1585", "DOI": "10.2106/00004623-199311000-00002", "volume": "75", "author": "D.W. Levine", "year": "1993", "unstructured": "Levine DW, Simmons BP, Koris MJ et al. (1993) A self-administered questionnaire for the assessment of severity of symptoms and functional status in carpal tunnel syndrome. J Bone Joint Surg Am 75:1585\u20131592", "journal-title": "J Bone Joint Surg Am"}, {"key": "51_CR24", "doi-asserted-by": "publisher", "first-page": "451", "DOI": "10.1016/S0733-8619(05)70267-X", "volume": "14", "author": "F.J. Marshall", "year": "1996", "unstructured": "Marshall FJ, Kieburtz K, McDermott M et al. (1996) Clinical research in neurology. From observation to experimentation. Neurol Clin 14:451\u2013466", "journal-title": "Neurol Clin"}, {"key": "51_CR25", "doi-asserted-by": "publisher", "first-page": "23", "DOI": "10.1006/enrs.2000.4042", "volume": "83", "author": "M. McDiarmid", "year": "2000", "unstructured": "McDiarmid M, Oliver M, Ruser J, Gucer P (2000) Male and female rate differences in carpal tunnel syndrome injuries attributes or job tasks? Environ Res 83:23\u201331", "journal-title": "Environ Res"}, {"key": "51_CR26", "first-page": "75", "volume": "50", "author": "J.L. Melvin", "year": "1969", "unstructured": "Melvin JL, Burnett CN, Johnson EW (1969) Median nerve conduction in pregnancy. Arch Phys Med Rehabil 50:75\u201380", "journal-title": "Arch Phys Med Rehabil"}, {"key": "51_CR27", "doi-asserted-by": "publisher", "first-page": "83", "DOI": "10.1007/BF00313722", "volume": "231", "author": "G. M\u00fchlau", "year": "1984", "unstructured": "M\u00fchlau G, Both R, Kunath H (1984) Carpal tunnel syndrome \u2014 course and prognosis. J Neurol 231:83\u201386", "journal-title": "J Neurol"}, {"key": "51_CR28", "doi-asserted-by": "publisher", "first-page": "1149", "DOI": "10.1002/mus.880111107", "volume": "11", "author": "P.A. Nathan", "year": "1988", "unstructured": "Nathan PA, Meadows KD, Doyle LS (1988) Relationship of age and sex to sensory conduction of the median nerve at the carpal tunnel and association of slowed conduction with symptoms. Muscle Nerve 11:1149\u20131153", "journal-title": "Muscle Nerve"}, {"key": "51_CR29", "doi-asserted-by": "publisher", "first-page": "711", "DOI": "10.1002/(SICI)1097-4598(199806)21:6<711::AID-MUS2>3.0.CO;2-A", "volume": "21", "author": "P.A. Nathan", "year": "1998", "unstructured": "Nathan PA, Keniston RC, Myers LD et al. (1998) Natural history of median nerve sensory conduction in industry: relationship to symptoms and carpal tunnel syndrome in 558 hands over 11 years. Muscle Nerve 21:711\u2013721", "journal-title": "Muscle Nerve"}, {"key": "51_CR30", "doi-asserted-by": "crossref", "first-page": "1431", "DOI": "10.1212/WNL.56.11.1431", "volume": "56", "author": "R.K. Olney", "year": "2001", "unstructured": "Olney RK (2001) Carpal tunnel syndrome. Complex issues with a \u201csimple\u201d condition. Neurology 56:1431\u20131432", "journal-title": "Neurology"}, {"key": "51_CR31", "doi-asserted-by": "publisher", "first-page": "48", "DOI": "10.1002/(SICI)1097-4598(199601)19:1<48::AID-MUS6>3.0.CO;2-8", "volume": "19", "author": "L. Padua", "year": "1996", "unstructured": "Padua L, Lo Monaco M, Valente EM, Tonali PA (1996) A useful electrophysiologic parameter for diagnosis of carpal tunnel syndrome. Muscle Nerve 19:48\u201353", "journal-title": "Muscle Nerve"}, {"key": "51_CR32", "doi-asserted-by": "publisher", "first-page": "679", "DOI": "10.1002/(SICI)1097-4598(199601)19:1<48::AID-MUS6>3.0.CO;2-8", "volume": "19", "author": "L. Padua", "year": "1996", "unstructured": "Padua L, Lo Monaco M, Gregori B et al. (1996) Double-peaked potential in the neurophysiological evaluation of carpal tunnel syndrome. Muscle Nerve 19: 679\u2013680", "journal-title": "Muscle Nerve"}, {"key": "51_CR33", "doi-asserted-by": "crossref", "first-page": "343", "DOI": "10.1111/j.1600-0404.1996.tb07077.x", "volume": "94", "author": "L. Padua", "year": "1996", "unstructured": "Padua L, Lo Monaco, Aulisa L et al. (1996) Surgical prognosis in carpal tunnel syndrome: usefulness of a preoperative neurophysiological assessment. Acta Neurol Scand 94:343\u2013346", "journal-title": "Acta Neurol Scand"}, {"key": "51_CR34", "doi-asserted-by": "publisher", "first-page": "211", "DOI": "10.1111/j.1600-0404.1997.tb00271.x", "volume": "96", "author": "L. Padua", "year": "1997", "unstructured": "Padua L, Lo Monaco M, Gregori B et al. (1997) Neurophysiological classification and sensitivity in 500 carpal tunnel syndrome hands. Acta Neurol Scand 96:211\u2013217", "journal-title": "Acta Neurol Scand"}, {"key": "51_CR35", "doi-asserted-by": "publisher", "first-page": "145", "DOI": "10.1007/BF02048482", "volume": "18", "author": "L. Padua", "year": "1997", "unstructured": "Padua L, Lo Monaco M, Padua R et al. (1997) Neurophysiological classification of carpal tunnel syndrome assessment of 600 symptomatic hands. Ital J Neurol Sci 18:145\u2013150", "journal-title": "Ital J Neurol Sci"}, {"key": "51_CR36", "first-page": "1045", "volume": "20", "author": "L. Padua", "year": "1997", "unstructured": "Padua L, Lo Monaco M, Moretti C, Tonali P (1997) Increase of early clinical diagnosis of carpal tunnel syndrome over the last years. Muscle Nerve 20:1045\u20131046", "journal-title": "Muscle Nerve"}, {"key": "51_CR37", "doi-asserted-by": "publisher", "first-page": "264", "DOI": "10.1002/(SICI)1097-4598(199802)21:2<264::AID-MUS24>3.0.CO;2-0", "volume": "21", "author": "L. Padua", "year": "1998", "unstructured": "Padua L, Lo Monaco M, Gregori B et al. (1998) Bilateral clinical-neurophysiological assessment of median nerve in carpal tunnel syndrome patients. Muscle Nerve 21:264\u2013265", "journal-title": "Muscle Nerve"}, {"key": "51_CR38", "doi-asserted-by": "publisher", "first-page": "357", "DOI": "10.1007/BF02341782", "volume": "19", "author": "L. Padua", "year": "1998", "unstructured": "Padua L, Padua R, Lo Monaco M et al. (1998) Natural history of carpal tunnel syndrome according to the neurophysiological classification. Ital J Neurol Sci 19:357\u2013361", "journal-title": "Ital J Neurol Sci"}, {"key": "51_CR39", "doi-asserted-by": "publisher", "first-page": "285", "DOI": "10.1007/BF00713854", "volume": "19", "author": "L. Padua", "year": "1998", "unstructured": "Padua L, Padua R, Lo Monaco et al. (1998) Italian multicentre study of carpal tunnel syndrome: study design. Ital J Neurol Sci 19:285\u2013289", "journal-title": "Ital J Neurol Sci"}, {"key": "51_CR40", "doi-asserted-by": "crossref", "first-page": "603", "DOI": "10.1016/S0266-7681(98)80010-7", "volume": "23", "author": "L. Padua", "year": "1998", "unstructured": "Padua L, Padua R, Nazzaro M, Tonali P (1998) Incidence of bilateral symptoms in carpal tunnel syndrome. J Hand Surg 23:603\u2013606", "journal-title": "J Hand Surg"}, {"key": "51_CR41", "doi-asserted-by": "publisher", "first-page": "284", "DOI": "10.1097/00003086-199801000-00036", "volume": "346", "author": "L. Padua", "year": "1998", "unstructured": "Padua L, Padua R, Lo Monaco M, Tonali P (1998) Postoperative outcome related to preoperative symptomatology. Clin Orthop 346:284\u2013285", "journal-title": "Clin Orthop"}, {"key": "51_CR42", "first-page": "123", "volume": "24", "author": "R. Padua", "year": "1998", "unstructured": "Padua R, Padua L, Romanini E et al. (1998) Versione italiana del questionario Boston Carpal Tunnel: valutazione preliminare. Giornale Italiano di Ortopedia e Traumatologia 24:123\u2013129", "journal-title": "Giornale Italiano di Ortopedia e Traumatologia"}, {"key": "51_CR43", "author": "R. Padua", "year": "1998", "unstructured": "Padua R, Romanini E, Zanoli G (1998) Analisi dei risultati nell\u2019apparato locomotore. Guerini editore, Milano", "volume-title": "Analisi dei risultati nell\u2019apparato locomotore"}, {"key": "51_CR44", "doi-asserted-by": "publisher", "first-page": "309", "DOI": "10.1007/s100720050046", "volume": "20", "author": "L. Padua", "year": "1999", "unstructured": "Padua L, Aprile I, Lo Monaco M et al. (1999) Italian multicentre study of carpal tunnel syndrome: clinical-neurophysiological picture and diagnostic pathway in 461 patients and differences between the populations enrolled in the northern, central and southern centres. Italian CTS Study Group. Ital J Neurol Sci 20:309\u2013313", "journal-title": "Ital J Neurol Sci"}, {"key": "51_CR45", "doi-asserted-by": "publisher", "first-page": "315", "DOI": "10.1007/s100720050047", "volume": "20", "author": "L. Padua", "year": "1999", "unstructured": "Padua L, Giannini F, Girlanda P et al. (1999) Usefulness of segmental and comparative tests in the electrodiagnosis of carpal tunnel syndrome: the Italian multicenter study. Italian CTS Study Group. Ital J Neurol Sci 20:315\u2013320", "journal-title": "Ital J Neurol Sci"}, {"key": "51_CR46", "doi-asserted-by": "publisher", "first-page": "579", "DOI": "10.1054/jhsb.1999.0255", "volume": "24", "author": "L. Padua", "year": "1999", "unstructured": "Padua L, Padua R, Aprile I, Tonali P (1999) Italian multicentre study of carpal tunnel syndrome: differences in the clinical and neurophysiological features between male and female patients. J Hand Surg Br 24:579\u2013582", "journal-title": "J Hand Surg Br"}, {"key": "51_CR47", "doi-asserted-by": "crossref", "first-page": "1654", "DOI": "10.1212/WNL.53.8.1654", "volume": "53", "author": "L. Padua", "year": "1999", "unstructured": "Padua L, Padua R, Lo Monaco M et al. (1999) Multiperspective assessment of carpal tunnel syndrome: a multicenter study. Italian CTS Study Group. Neurology 53:1654\u20131659", "journal-title": "Neurology"}, {"key": "51_CR48", "doi-asserted-by": "crossref", "first-page": "1654", "DOI": "10.1212/WNL.53.8.1654", "volume": "53", "author": "L. Padua", "year": "1999", "unstructured": "Padua L, Padua R, Lo Monaco M et al. (1999) Multiperspective assessment of carpal tunnel syndrome: a multicenter study: Italian CTS Study Group. Neurology 53:1654\u20131659", "journal-title": "Neurology"}, {"key": "51_CR49", "doi-asserted-by": "publisher", "first-page": "1946", "DOI": "10.1016/S1388-2457(01)00637-X", "volume": "112", "author": "L. Padua", "year": "2001", "unstructured": "Padua L, Aprile I, Caliandro P et al. The Italian Carpal Tunnel Syndrome Study Group (2001) Symptoms and neurophysiological picture of carpal tunnel syndrome in pregnancy. Clin Neurophysiol 112:1946\u20131951", "journal-title": "Clin Neurophysiol"}, {"key": "51_CR50", "doi-asserted-by": "publisher", "first-page": "369", "DOI": "10.1097/00001648-200105000-00024", "volume": "12", "author": "L. Padua", "year": "2001", "unstructured": "Padua L, Aprile I, Caliandro P et al. Gruppo Italiano Studio Sindrome Tunnel Carpale (2001) Is the occurrence of carpal tunnel syndrome inmen underestimated? Epidemiology 12:369", "journal-title": "Epidemiology"}, {"key": "51_CR51", "doi-asserted-by": "crossref", "first-page": "1459", "DOI": "10.1212/WNL.56.11.1459", "volume": "56", "author": "L. Padua", "year": "2001", "unstructured": "Padua L, Padua R, Aprile I et al. Italian CTS Study Group (2001) Multiperspective follow-up of untreated carpal tunnel syndrome. A multicenter study. Neurology 56:1459\u201366", "journal-title": "Neurology"}, {"key": "51_CR52", "doi-asserted-by": "crossref", "first-page": "1459", "DOI": "10.1212/WNL.56.11.1459", "volume": "56", "author": "L. Padua", "year": "2001", "unstructured": "Padua L, Padua R, Aprile I et al. The Italian CTS Study Group. Carpal tunnel syndrome (2001) Multiperspective follow-up of untreated carpal tunnel syndrome: a multicenter study. Neurology 56:1459\u20131466", "journal-title": "Neurology"}, {"key": "51_CR53", "doi-asserted-by": "crossref", "first-page": "1643", "DOI": "10.1212/01.WNL.0000034764.80136.EF", "volume": "59", "author": "L. Padua", "year": "2002", "unstructured": "Padua L, Aprile I, Caliandro P et al. Italian Carpal Tunnel Syndrome Study Group (2002) Carpal tunnel syndrome in pregnancy: multiperspective follow-up of untreated cases. Neurology 59:1643\u20131646", "journal-title": "Neurology"}, {"key": "51_CR54", "doi-asserted-by": "publisher", "first-page": "905", "DOI": "10.1002/mus.880121106", "volume": "12", "author": "W.S. Pease", "year": "1989", "unstructured": "Pease WS, Cannell CD, Johnson EW (1989) Median to radial latency difference test in mild carpal tunnel syndrome. Muscle Nerve 12:905\u2013909", "journal-title": "Muscle Nerve"}, {"key": "51_CR55", "doi-asserted-by": "publisher", "first-page": "1253", "DOI": "10.1002/mus.880151106", "volume": "15", "author": "D.C. Preston", "year": "1992", "unstructured": "Preston DC, Logigian E (1992) Lumbrical and interossei recording in carpal tunnel syndrome. Muscle Nerve 15:1253\u20131257", "journal-title": "Muscle Nerve"}, {"key": "51_CR56", "doi-asserted-by": "publisher", "first-page": "1165", "DOI": "10.1002/(SICI)1097-4598(199909)22:9<1165::AID-MUS1>3.0.CO;2-1", "volume": "22", "author": "R. Rosenbaum", "year": "1999", "unstructured": "Rosenbaum R (1999) Carpal tunnel syndrome and the myth of El Dorado. Muscle Nerve 22:1165\u20131167", "journal-title": "Muscle Nerve"}, {"key": "51_CR57", "doi-asserted-by": "crossref", "first-page": "330", "DOI": "10.1016/0168-5597(94)90120-1", "volume": "93", "author": "S. Rossi", "year": "1994", "unstructured": "Rossi S, Giannini F, Passero S et al. (1994) Sensory neural conduction ofmedian nerve from digits and palm stimulation in carpal tunnel syndrome. Electroencephalogr Clin Neurophysiol 93:330\u2013334", "journal-title": "Electroencephalogr Clin Neurophysiol"}, {"key": "51_CR58", "doi-asserted-by": "publisher", "first-page": "98", "DOI": "10.1016/S0266-7681(98)80232-5", "volume": "23", "author": "P. Seror", "year": "1998", "unstructured": "Seror P (1998) Pregnancy-related carpal tunnel syndrome. J Hand Surg Br 23:98\u2013101", "journal-title": "J Hand Surg Br"}, {"key": "51_CR59", "doi-asserted-by": "publisher", "first-page": "285", "DOI": "10.1016/0924-980X(95)00197-S", "volume": "97", "author": "G.L. Sheean", "year": "1995", "unstructured": "Sheean GL, Houser MK, Murray NM (1995) Lumbrical-interosseus latency comparison in the diagnosis of carpal tunnel syndrome. Electroencephalogr Clin Neurophysiol 97:285\u2013289", "journal-title": "Electroencephalogr Clin Neurophysiol"}, {"key": "51_CR60", "doi-asserted-by": "publisher", "first-page": "99", "DOI": "10.1002/mus.880100202", "volume": "10", "author": "J.C. Stevens", "year": "1987", "unstructured": "Stevens JC (1987) AAEE Minimonograph #26: The electrodiagnosis of carpal tunnel syndrome. Muscle Nerve 10:99\u2013113", "journal-title": "Muscle Nerve"}, {"key": "51_CR61", "doi-asserted-by": "crossref", "first-page": "541", "DOI": "10.1016/S0025-6196(12)60461-3", "volume": "67", "author": "J.C. Stevens", "year": "1992", "unstructured": "Stevens JC, Beard CM, O\u2019Fallon WM, Kurland LT (1992) Conditions associated with carpal tunnel syndrome. Mayo Clin Proc 67:541\u2013548", "journal-title": "Mayo Clin Proc"}, {"key": "51_CR62", "doi-asserted-by": "publisher", "first-page": "1285", "DOI": "10.1016/S0003-9993(98)90276-3", "volume": "79", "author": "K.A. Stolp-Smith", "year": "1998", "unstructured": "Stolp-Smith KA, Pascoe MK, Ogburn PL (1998) Carpal tunnel syndrome in pregnancy: frequency, severity, and prognosis. Arch Phys Med Rehabil 79:1285\u20131287", "journal-title": "Arch Phys Med Rehabil"}, {"key": "51_CR63", "doi-asserted-by": "crossref", "first-page": "635", "DOI": "10.1001/archneur.1967.00470240073010", "volume": "16", "author": "J.E. Thomas", "year": "1967", "unstructured": "Thomas JE, Lambert EH, Cseuz KA (1967) Electrodiagnostic aspects of the carpal tunnel syndrome. Arch Neurol 16:635\u2013641", "journal-title": "Arch Neurol"}, {"key": "51_CR64", "doi-asserted-by": "crossref", "first-page": "493", "DOI": "10.1016/0002-9378(67)90562-5", "volume": "15", "author": "S.M. Tobin", "year": "1967", "unstructured": "Tobin SM (1967) Carpal tunnel syndrome in pregnancy. Am J Obstet Gynecol 15:493\u2013498", "journal-title": "Am J Obstet Gynecol"}, {"key": "51_CR65", "doi-asserted-by": "publisher", "first-page": "139", "DOI": "10.1007/s100720050022", "volume": "20", "author": "P. Tonali", "year": "1999", "unstructured": "Tonali P, Padua L, Sanguinetti C et al. (1999) Outcome research and patient-oriented measures in the multiperspective assessment of neurological andmusculoskeletal disorders. Consensus Conference: Third Roman Neurophysiology day, Outcome Research in Neurology and in Musculoskeletal Disorders \u2014 24 October 1998. Ital J Neurol Sci 20:139\u2013140", "journal-title": "Ital J Neurol Sci"}, {"key": "51_CR66", "doi-asserted-by": "publisher", "first-page": "139", "DOI": "10.1007/s100720050022", "volume": "20", "author": "P. Tonali", "year": "1999", "unstructured": "Tonali P, Padua L, Sanguinetti C et al. (1999) Outcome research and patient-oriented measures in the multiperspective assessment of neurological and musculoskeletal disorders. Consensus Conference: Third Roman Neurophysiology day, Outcome Research in Neurology and inMusculoskeletal Disorders \u2014 24 October 1998. Ital J Neurol Sci 20:139\u2013140", "journal-title": "Ital J Neurol Sci"}, {"key": "51_CR67", "doi-asserted-by": "publisher", "first-page": "735", "DOI": "10.1002/mus.880120906", "volume": "12", "author": "A. Uncini", "year": "1989", "unstructured": "Uncini A, Lange DJ, Solomon M et al. (1989) Ring finger testing in carpal tunnel syndrome: a comparative study of diagnostic utility. Muscle Nerve 12:735\u2013741", "journal-title": "Muscle Nerve"}, {"key": "51_CR68", "doi-asserted-by": "publisher", "first-page": "1366", "DOI": "10.1002/mus.880161215", "volume": "16", "author": "A. Uncini", "year": "1993", "unstructured": "Uncini A, Di Muzio A, Awad J et al. (1993) Sensitivity of three median-to-ulnar comparative tests in diagnosis of mild carpal tunnel syndrome. Muscle Nerve 16:1366\u20131373", "journal-title": "Muscle Nerve"}, {"key": "51_CR69", "first-page": "277", "volume": "128", "author": "A.J. Voitk", "year": "1983", "unstructured": "Voitk AJ, Mueller JC, Farlinger DE, Johnston RU (1983) Carpal tunnel syndrome in pregnancy. Can Med Assoc J 128:277\u2013281", "journal-title": "Can Med Assoc J"}, {"key": "51_CR70", "doi-asserted-by": "publisher", "first-page": "93", "DOI": "10.1016/0266-7681(90)90057-B", "volume": "15", "author": "J.S. Wand", "year": "1990", "unstructured": "Wand JS. Carpal tunnel syndrome in pregnancy and lactation (1990) J Hand Surg Br 15:93\u201395", "journal-title": "J Hand Surg Br"}, {"key": "51_CR71", "author": "J.E. Ware Jr", "year": "1994", "unstructured": "Ware JE Jr, Kosinski M, Keller SD (1994) SF-36 physical and mental health summary scales: a user\u2019s manual. New England Medical Center, Boston", "volume-title": "SF-36 physical and mental health summary scales: a user\u2019s manual"}], "container-title": ["Carpal Tunnel Syndrome"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-3-540-49008-1_51", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 2, 28]], "date-time": "2019-02-28T07:49:24Z", "timestamp": 1551340164000}, "score": 25.615295, "issued": {"date-parts": [[null]]}, "ISBN": ["9783540223870", "9783540490081"], "references-count": 71, "URL": "http://dx.doi.org/10.1007/978-3-540-49008-1_51", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T13:37:46Z", "timestamp": 1575293866039}, "reference-count": 40, "publisher": "Springer Science and Business Media LLC", "issue": "10", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2008, 8, 4]], "date-time": "2008-08-04T00:00:00Z", "timestamp": 1217808000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2008, 11]]}, "DOI": "10.1038/bmt.2008.226", "type": "journal-article", "created": {"date-parts": [[2008, 8, 4]], "date-time": "2008-08-04T15:41:37Z", "timestamp": 1217864497000}, "page": "659-666", "source": "Crossref", "is-referenced-by-count": 7, "title": ["Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML"], "prefix": "10.1038", "volume": "42", "author": [{"given": "T J", "family": "Nevill", "sequence": "first", "affiliation": []}, {"given": "D E", "family": "Hogge", "sequence": "additional", "affiliation": []}, {"given": "C L", "family": "Toze", "sequence": "additional", "affiliation": []}, {"given": "S H", "family": "Nantel", "sequence": "additional", "affiliation": []}, {"given": "M M", "family": "Power", "sequence": "additional", "affiliation": []}, {"given": "Y R", "family": "Abou Mourad", "sequence": "additional", "affiliation": []}, {"given": "K W", "family": "Song", "sequence": "additional", "affiliation": []}, {"given": "J C", "family": "Lavoie", "sequence": "additional", "affiliation": []}, {"given": "D L", "family": "Forrest", "sequence": "additional", "affiliation": []}, {"given": "M J", "family": "Barnett", "sequence": "additional", "affiliation": []}, {"given": "J D", "family": "Shepherd", "sequence": "additional", "affiliation": []}, {"given": "J Y", "family": "Nitta", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Wong", "sequence": "additional", "affiliation": []}, {"given": "H J", "family": "Sutherland", "sequence": "additional", "affiliation": []}, {"given": "C A", "family": "Smith", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2008, 8, 4]]}, "reference": [{"key": "BFbmt2008226_CR1", "first-page": "1364", "volume": "65", "author": "SD Michels", "year": "1985", "unstructured": "Michels SD, McKenna RW, Arthur DC, Brunning RD . Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985; 65: 1364\u20131372.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR2", "doi-asserted-by": "publisher", "first-page": "43", "DOI": "10.1182/blood-2002-11-3343", "volume": "102", "author": "SM Smith", "year": "2003", "unstructured": "Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago experience. Blood 2003; 102: 43\u201352.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR3", "doi-asserted-by": "publisher", "first-page": "197", "DOI": "10.1309/NQ3PMV4U8YV39JWJ", "volume": "127", "author": "ZN Singh", "year": "2007", "unstructured": "Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007; 127: 197\u2013205.", "journal-title": "Am J Clin Pathol"}, {"key": "BFbmt2008226_CR4", "first-page": "1990", "volume": "9", "author": "CH Pui", "year": "1995", "unstructured": "Pui CH, Relling MV, Rivera GK, Hancock ML, Raimondi SC, Heslop HE et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 1995; 9: 1990\u20131996.", "journal-title": "Leukemia"}, {"key": "BFbmt2008226_CR5", "doi-asserted-by": "publisher", "first-page": "13", "DOI": "10.1046/j.1365-2141.2000.01843.x", "volume": "109", "author": "CH Pui", "year": "2000", "unstructured": "Pui CH, Relling MV . Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 2000; 109: 13\u201323.", "journal-title": "Br J Haematol"}, {"key": "BFbmt2008226_CR6", "doi-asserted-by": "publisher", "first-page": "2292", "DOI": "10.1182/blood-2002-04-1199", "volume": "100", "author": "JW Vardiman", "year": "2002", "unstructured": "Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292\u20132302.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR7", "first-page": "2322", "volume": "92", "author": "D Grimwade", "year": "1998", "unstructured": "Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322\u20132333.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR8", "doi-asserted-by": "publisher", "first-page": "81", "DOI": "10.1016/S0889-8588(18)30259-4", "volume": "7", "author": "HM Kantarjian", "year": "1993", "unstructured": "Kantarjian HM, Estey EH, Keating MJ . Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol/Oncol Clin N Am 1993; 7: 81\u2013106.", "journal-title": "Hematol/Oncol Clin N Am"}, {"key": "BFbmt2008226_CR9", "doi-asserted-by": "publisher", "first-page": "183", "DOI": "10.1038/sj.bmt.1705226", "volume": "37", "author": "N Kr\u00f6ger", "year": "2006", "unstructured": "Kr\u00f6ger N, Brand R, van Biezen A, Cahn J-Y, Slavin S, Blaise D et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2006; 37: 183\u2013189.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2008226_CR10", "doi-asserted-by": "publisher", "first-page": "630", "DOI": "10.1046/j.1365-2141.1998.01030.x", "volume": "103", "author": "DL Forrest", "year": "1998", "unstructured": "Forrest DL, Nevill TJ, Horsman DE, Brockington DA, Fung HC, Toze CL et al. Bone marrow transplantation for adults with acute leukaemia and 11q23 chromosomal abnormalities. Br J Haematol 1998; 103: 630\u2013638.", "journal-title": "Br J Haematol"}, {"issue": "suppl 1", "key": "BFbmt2008226_CR11", "first-page": "96a", "volume": "86", "author": "HC Fung", "year": "1995", "unstructured": "Fung HC, Nantel SH, Phillips GL, Shepherd JD, Sutherland HJ, Klingemann H-G et al. Allogeneic bone marrow transplantation (BMT) for adults with secondary myelodysplastic syndrome (MDS) or secondary acute myelogenous leukemia (AML). Blood 1995; 86 (suppl 1): 96a.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR12", "first-page": "2578", "volume": "89", "author": "JE Anderson", "year": "1997", "unstructured": "Anderson JE, Gooley TA, Schoch G, Anasetti C, Bensinger WI, Clift RA et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89: 2578\u20132585.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR13", "doi-asserted-by": "publisher", "first-page": "737", "DOI": "10.1038/sj.bmt.1700971", "volume": "20", "author": "KK Ballen", "year": "1997", "unstructured": "Ballen KK, Gilliland DG, Guinan EC, Hsieh C-C, Parsons SK, Rimm IJ et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant 1997; 20: 737\u2013743.", "journal-title": "Bone Marrow Transplant"}, {"issue": "suppl 1", "key": "BFbmt2008226_CR14", "first-page": "S35", "volume": "25", "author": "TJ Nevill", "year": "2001", "unstructured": "Nevill TJ, Shepherd JD, Brockington DA, Le A, Sutherland HJ, Toze CL et al. High-dose chemo/radiotherapy and stem cell transplantation for therapy-induced myelodysplasia or acute myelogenous leukemia: outcome analysis and significance of marrow karyotype. Leuk Res 2001; 25 (suppl 1): S35\u2013S36.", "journal-title": "Leuk Res"}, {"key": "BFbmt2008226_CR15", "doi-asserted-by": "publisher", "first-page": "427", "DOI": "10.1182/blood.V100.2.427", "volume": "100", "author": "DR Barnard", "year": "2002", "unstructured": "Barnard DR, Lange B, Alonzo TA, Buckley J, Kobrinsky JN, Gold S et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood 2002; 100: 427\u2013434.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR16", "first-page": "1910", "volume": "92", "author": "TJ Nevill", "year": "1998", "unstructured": "Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998; 92: 1910\u20131917.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR17", "first-page": "2079", "volume": "89", "author": "P Greenberg", "year": "1997", "unstructured": "Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079\u20132088.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR18", "doi-asserted-by": "publisher", "first-page": "1049", "DOI": "10.7326/0003-4819-111-12-1049_2", "volume": "111", "author": "A Grigg", "year": "1989", "unstructured": "Grigg A, Shepherd JD, Phillips GL . Busulphan and phenytoin. Ann Intern Med 1989; 111: 1049\u20131050 (letter) (correction 112:313,1990).", "journal-title": "Ann Intern Med"}, {"key": "BFbmt2008226_CR19", "doi-asserted-by": "publisher", "first-page": "729", "DOI": "10.1056/NEJM198603203141201", "volume": "314", "author": "R Storb", "year": "1986", "unstructured": "Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729\u2013735.", "journal-title": "N Engl J Med"}, {"issue": "suppl B", "key": "BFbmt2008226_CR20", "first-page": "B58", "volume": "17", "author": "TE Thomas", "year": "1994", "unstructured": "Thomas TE, Abraham SJR, Phillips GL, Lansdorp PE . Depletion of CD3+ cells from allogeneic bone marrow grafts using high gradient magnetic separation. Clin Invest Med 1994; 17 (suppl B): B58.", "journal-title": "Clin Invest Med"}, {"key": "BFbmt2008226_CR21", "first-page": "2834", "volume": "79", "author": "M Attal", "year": "1992", "unstructured": "Attal M, Huguet F, Rubie H, Huynh A, Charet JP, Payen JL et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834\u20132840.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR22", "doi-asserted-by": "publisher", "first-page": "457", "DOI": "10.1080/01621459.1958.10501452", "volume": "53", "author": "EL Kaplan", "year": "1958", "unstructured": "Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.", "journal-title": "J Am Stat Assoc"}, {"key": "BFbmt2008226_CR23", "doi-asserted-by": "publisher", "first-page": "1141", "DOI": "10.1214/aos/1176350951", "volume": "16", "author": "JR Gray", "year": "1988", "unstructured": "Gray JR . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141\u20131154.", "journal-title": "Ann Stat"}, {"key": "BFbmt2008226_CR24", "first-page": "187", "volume": "34", "author": "DR Cox", "year": "1972", "unstructured": "Cox DR . Regression models and life tables. J R Stat Soc B 1972; 34: 187\u2013220.", "journal-title": "J R Stat Soc B"}, {"key": "BFbmt2008226_CR25", "doi-asserted-by": "publisher", "first-page": "1707", "DOI": "10.1200/JCO.1990.8.10.1707", "volume": "8", "author": "G Longmore", "year": "1990", "unstructured": "Longmore G, Guinan EC, Weinstein HJ, Gelber RD, Rappeport JM, Antin JH . Bone marrow transplantation for myelodysplasia and secondary acute non-lymphocytic leukemia. J Clin Oncol 1990; 8: 1707\u20131714.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt2008226_CR26", "doi-asserted-by": "publisher", "first-page": "731", "DOI": "10.1200/JCO.1987.5.5.731", "volume": "5", "author": "M Sargur", "year": "1987", "unstructured": "Sargur M, Buckner CD, Appelbaum FR, Stewart P, Deeg HJ, Weiden PL et al. Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease. J Clin Oncol 1987; 5: 731\u2013734.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt2008226_CR27", "doi-asserted-by": "publisher", "first-page": "963", "DOI": "10.1200/JCO.2000.18.5.963", "volume": "18", "author": "I Yakoub-Agha", "year": "2000", "unstructured": "Yakoub-Agha I, de La Salmoni\u00e9re P, Ribaud P, Sutton L, Wattel E, Kuentz M et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients\u2014report of the French Society of Bone Marrow Transplantation. J Clin Oncol 2000; 18: 963\u2013971.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt2008226_CR28", "doi-asserted-by": "publisher", "first-page": "1379", "DOI": "10.1182/blood-2007-02-076307", "volume": "110", "author": "C Chang", "year": "2007", "unstructured": "Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110: 1379\u20131387.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR29", "first-page": "81a", "volume": "110", "author": "N Kroeger", "year": "2007", "unstructured": "Kroeger N, Brand R, van Biezen A, Niederwieser D, de Witte T . Allogeneic stem cell transplantation for therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia. A report from the MDS subcommittee of the chronic leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 110: 81a.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR30", "doi-asserted-by": "publisher", "first-page": "2134", "DOI": "10.1200/JCO.2001.19.8.2134", "volume": "19", "author": "RP Witherspoon", "year": "2001", "unstructured": "Witherspoon RP, Deeg HJ, Storer B, Anasetti C, Storb R, Appelbaum FR . Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001; 19: 2134\u20132141.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt2008226_CR31", "doi-asserted-by": "publisher", "first-page": "1682", "DOI": "10.1056/NEJM199112123252402", "volume": "325", "author": "CH Pui", "year": "1991", "unstructured": "Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682\u20131687.", "journal-title": "N Engl J Med"}, {"key": "BFbmt2008226_CR32", "doi-asserted-by": "publisher", "first-page": "1049", "DOI": "10.1002/(SICI)1097-0142(19970301)79:5<1049::AID-CNCR24>3.0.CO;2-0", "volume": "79", "author": "ES Sandler", "year": "1997", "unstructured": "Sandler ES, Friedman DJ, Mustafa MM, Winick NJ, Bowman WP, Buchanan GR . Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Cancer 1997; 79: 1049\u20131054.", "journal-title": "Cancer"}, {"key": "BFbmt2008226_CR33", "doi-asserted-by": "publisher", "first-page": "21", "DOI": "10.1038/sj.bmt.1701517", "volume": "23", "author": "AM Leahey", "year": "1999", "unstructured": "Leahey AM, Friedman DL, Bunin NJ . Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. Bone Marrow Transplant 1999; 23: 21\u201325.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2008226_CR34", "doi-asserted-by": "publisher", "first-page": "735", "DOI": "10.1038/sj.bmt.1701962", "volume": "24", "author": "GA Hale", "year": "1999", "unstructured": "Hale GA, Heslop HE, Bowman LC, Rochester RA, Pui C-H, Brenner MK et al. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant 1999; 24: 735\u2013739.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2008226_CR35", "doi-asserted-by": "publisher", "first-page": "395", "DOI": "10.1002/gcc.10043", "volume": "33", "author": "MK Andersen", "year": "2002", "unstructured": "Andersen MK, Larson RA, Mauritzon N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J . Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002; 33: 395\u2013400.", "journal-title": "Genes Chromosomes Cancer"}, {"key": "BFbmt2008226_CR36", "doi-asserted-by": "publisher", "first-page": "1616", "DOI": "10.1182/blood-2003-12-4207", "volume": "104", "author": "A Ho", "year": "2004", "unstructured": "Ho A, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616\u20131623.", "journal-title": "Blood"}, {"key": "BFbmt2008226_CR37", "doi-asserted-by": "publisher", "first-page": "843", "DOI": "10.1038/sj.bmt.1705801", "volume": "40", "author": "R Nakamura", "year": "2007", "unstructured": "Nakamura R, Rodriguez R, Palmer J, Stein A, Naing A, Tsai N et al. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and mephalan is associated with durable disease control in myelodysplastic syndrome. Bone Marrow Transplant 2007; 40: 843\u2013850.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2008226_CR38", "doi-asserted-by": "publisher", "first-page": "65", "DOI": "10.1016/j.bbmt.2004.10.001", "volume": "11", "author": "BL Scott", "year": "2005", "unstructured": "Scott BL, Storer B, Loken MR, Storb R, Appelbaum FR, Deeg HJ . Pretransplantation induction chemotherapy and post-transplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005; 11: 65\u201373.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt2008226_CR39", "doi-asserted-by": "publisher", "first-page": "175", "DOI": "10.1056/NEJM200101183440303", "volume": "344", "author": "WI Bensinger", "year": "2001", "unstructured": "Bensinger WI, Martin RJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175\u2013181.", "journal-title": "N Engl J Med"}, {"key": "BFbmt2008226_CR40", "doi-asserted-by": "publisher", "first-page": "1525", "DOI": "10.1182/blood-2002-01-0048", "volume": "100", "author": "S Couban", "year": "2002", "unstructured": "Couban S, Simpson DR, Barnett MJ, Bredeson C, Huebsch L, Howsan-Jan K et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525\u20131531.", "journal-title": "Blood"}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bmt2008226.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt2008226", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt2008226.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 13]], "date-time": "2019-04-13T14:12:20Z", "timestamp": 1555164740000}, "score": 25.421144, "issued": {"date-parts": [[2008, 8, 4]]}, "references-count": 40, "journal-issue": {"published-print": {"date-parts": [[2008, 11]]}, "issue": "10"}, "alternative-id": ["BFbmt2008226"], "URL": "http://dx.doi.org/10.1038/bmt.2008.226", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}], "subject": ["Transplantation", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T20:51:49Z", "timestamp": 1574283109489}, "reference-count": 77, "publisher": "Springer Science and Business Media LLC", "issue": "8", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2009, 3, 2]], "date-time": "2009-03-02T00:00:00Z", "timestamp": 1235952000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2009, 4]]}, "DOI": "10.1038/bmt.2009.28", "type": "journal-article", "created": {"date-parts": [[2009, 3, 2]], "date-time": "2009-03-02T11:47:05Z", "timestamp": 1235994425000}, "page": "597-609", "source": "Crossref", "is-referenced-by-count": 25, "title": ["The evolution of hematopoietic SCT in myelodysplastic syndrome"], "prefix": "10.1038", "volume": "43", "author": [{"given": "T", "family": "Kindwall-Keller", "sequence": "first", "affiliation": []}, {"given": "L M", "family": "Isola", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2009, 3, 2]]}, "reference": [{"key": "BFbmt200928_CR1", "doi-asserted-by": "publisher", "first-page": "1536", "DOI": "10.1002/cncr.22570", "volume": "109", "author": "X Ma", "year": "2007", "unstructured": "Ma X, Does M, Raza A, Mayne ST . Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007; 109: 1536\u20131542.", "journal-title": "Cancer"}, {"key": "BFbmt200928_CR2", "doi-asserted-by": "publisher", "first-page": "2429", "DOI": "10.1200/JCO.2002.04.117", "volume": "20", "author": "LR Silverman", "year": "2002", "unstructured": "Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429\u20132440.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt200928_CR3", "doi-asserted-by": "publisher", "first-page": "3895", "DOI": "10.1200/JCO.2005.05.4346", "volume": "24", "author": "LR Silverman", "year": "2006", "unstructured": "Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895\u20133903.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt200928_CR4", "unstructured": "Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch R et al. Azacitidine treatment prolongs overall survival in higher-risk MDS patients compared with conventional care regimens: results of AZA-001 phase III study. Blood 2007; 110: abstract 817."}, {"key": "BFbmt200928_CR5", "doi-asserted-by": "publisher", "first-page": "1794", "DOI": "10.1002/cncr.21792", "volume": "106", "author": "H Kantarjian", "year": "2006", "unstructured": "Kantarjian H, Issa J-P, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794\u20131803.", "journal-title": "Cancer"}, {"key": "BFbmt200928_CR6", "doi-asserted-by": "publisher", "first-page": "549", "DOI": "10.1056/NEJMoa041668", "volume": "352", "author": "A List", "year": "2005", "unstructured": "List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549\u2013557.", "journal-title": "N Engl J Med"}, {"key": "BFbmt200928_CR7", "doi-asserted-by": "publisher", "first-page": "1456", "DOI": "10.1056/NEJMoa061292", "volume": "355", "author": "A List", "year": "2006", "unstructured": "List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456\u20131465.", "journal-title": "N Engl J Med"}, {"key": "BFbmt200928_CR8", "doi-asserted-by": "publisher", "first-page": "2134", "DOI": "10.1200/JCO.2001.19.8.2134", "volume": "19", "author": "RP Witherspoon", "year": "2001", "unstructured": "Witherspoon RP, Deeg HJ, Storer B, Anasetti C, Storb R, Appelbaum FR . Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001; 19: 2134\u20132141.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt200928_CR9", "doi-asserted-by": "publisher", "first-page": "1943", "DOI": "10.1182/blood.V99.6.1943", "volume": "99", "author": "H Castro-Malaspina", "year": "2002", "unstructured": "Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99: 1943\u20131951.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR10", "doi-asserted-by": "publisher", "first-page": "1201", "DOI": "10.1182/blood-2002-02-0527", "volume": "100", "author": "HJ Deeg", "year": "2002", "unstructured": "Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100: 1201\u20131207.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR11", "doi-asserted-by": "publisher", "first-page": "3439", "DOI": "10.1200/JCO.2005.05.694", "volume": "23", "author": "H Wallen", "year": "2005", "unstructured": "Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005; 23: 3439\u20133446.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt200928_CR12", "doi-asserted-by": "publisher", "first-page": "579", "DOI": "10.1182/blood-2004-01-0338", "volume": "104", "author": "CS Cutler", "year": "2004", "unstructured": "Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579\u2013585.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR13", "doi-asserted-by": "publisher", "first-page": "1351", "DOI": "10.1002/cncr.23697", "volume": "113", "author": "H Kantarjian", "year": "2008", "unstructured": "Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system. Cancer 2008; 113: 1351\u20131361.", "journal-title": "Cancer"}, {"key": "BFbmt200928_CR14", "doi-asserted-by": "publisher", "first-page": "895", "DOI": "10.1182/blood-2008-03-143735", "volume": "112", "author": "EP Alessandrino", "year": "2008", "unstructured": "Alessandrino EP, Della Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F et al. WHO classification and WPSS predict post transplant outcome in patients with myelodysplastic syndrome: a study from the GITMO (gruppo italiano trapianto di midollo osseo). Blood 2008; 112: 895\u2013902.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR15", "doi-asserted-by": "publisher", "first-page": "2326", "DOI": "10.1182/blood.V98.8.2326", "volume": "98", "author": "T de Witte", "year": "2001", "unstructured": "de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326\u20132331.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR16", "doi-asserted-by": "publisher", "first-page": "396", "DOI": "10.1038/sj.leu.2403640", "volume": "19", "author": "K Nakai", "year": "2005", "unstructured": "Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 2005; 19: 396\u2013401.", "journal-title": "Leukemia"}, {"key": "BFbmt200928_CR17", "doi-asserted-by": "publisher", "first-page": "2744", "DOI": "10.1182/blood-2007-03-078592", "volume": "110", "author": "C Kahl", "year": "2007", "unstructured": "Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG et al. Relapse risk in patients with malignant disease given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007; 110: 2744\u20132748.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR18", "doi-asserted-by": "publisher", "first-page": "1133", "DOI": "10.1002/cncr.22508", "volume": "109", "author": "HM Kantarjian", "year": "2007", "unstructured": "Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007; 109: 1133\u20131137.", "journal-title": "Cancer"}, {"key": "BFbmt200928_CR19", "unstructured": "De Padua Silva L, de Lima M, Kantarjian H, Champlin R, Faderl S, Giralt S et al. Outcome of allogeneic stem cell transplantation after hypomethylating therapy with 2\u2032-deoxy-5 azacytidine for patients with myelodysplastic syndrome. Blood 2007; 110: abstract 1468."}, {"key": "BFbmt200928_CR20", "unstructured": "Field T, Perkins J, Alsina M, Ayala E, Fernandez HF, Janssen W et al. Pre-transplant 5-Azacitidine may improve outcome of allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS). Blood 2006; 108: abstract 3664."}, {"key": "BFbmt200928_CR21", "unstructured": "SEER Cancer Statistics Review 1975\u20132004. National Cancer Institute."}, {"key": "BFbmt200928_CR22", "doi-asserted-by": "publisher", "first-page": "127", "DOI": "10.1111/j.1399-0012.2005.00453.x", "volume": "20", "author": "M Ditschkowski", "year": "2006", "unstructured": "Ditschkowski M, Elmaagacli AH, Trenschel R, Steckel NK, Koldehoff M, Beelen DW . Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients. Clin Transplant 2006; 20: 127\u2013131.", "journal-title": "Clin Transplant"}, {"key": "BFbmt200928_CR23", "doi-asserted-by": "publisher", "first-page": "1043", "DOI": "10.1038/sj.bmt.1701210", "volume": "21", "author": "W Du", "year": "1998", "unstructured": "Du W, Dansey R, Abella EM, Baynes R, Peters WP, Klein J et al. Successful allogeneic bone marrow transplantation in selected patients over 50 years of age\u2014a single institution's experience. Bone Marrow Transplant 1998; 21: 1043\u20131047.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt200928_CR24", "doi-asserted-by": "publisher", "first-page": "1810", "DOI": "10.1182/blood-2004-05-1947", "volume": "105", "author": "EP Alyea", "year": "2005", "unstructured": "Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810\u20131814.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR25", "doi-asserted-by": "publisher", "first-page": "5074", "DOI": "10.1200/JCO.2005.09.020", "volume": "23", "author": "Stem Cell Trialists' Collaborative Group", "year": "2005", "unstructured": "Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074\u20135087.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt200928_CR26", "doi-asserted-by": "publisher", "first-page": "3685", "DOI": "10.1200/JCO.2001.19.16.3685", "volume": "19", "author": "C Cutler", "year": "2001", "unstructured": "Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685\u20133691.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt200928_CR27", "doi-asserted-by": "publisher", "first-page": "19", "DOI": "10.1038/sj.bmt.1705688", "volume": "40", "author": "BR Dey", "year": "2007", "unstructured": "Dey BR, Shaffer J, Yee AJ, McAfee S, Caron M, Power K et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant 2007; 40: 19\u201327.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt200928_CR28", "doi-asserted-by": "publisher", "first-page": "4370", "DOI": "10.1182/blood.V99.12.4370", "volume": "99", "author": "P Guardiola", "year": "2002", "unstructured": "Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002; 99: 4370\u20134378.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR29", "first-page": "373", "volume": "91", "author": "S Ducastelle", "year": "2006", "unstructured": "Ducastelle S, Ad\u00e8s L, Gardin C, Dombret H, Pr\u00e9bet T, Deconinck E et al. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Haematologica 2006; 91: 373\u2013376.", "journal-title": "Haematologica"}, {"key": "BFbmt200928_CR30", "first-page": "750", "volume": "91", "author": "T de Witte", "year": "2006", "unstructured": "de Witte T, Brand R, van Biezen A, Delforge M, Biersack H, Or R et al. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. Haematologica 2006; 91: 750\u2013756.", "journal-title": "Haematologica"}, {"key": "BFbmt200928_CR31", "doi-asserted-by": "publisher", "first-page": "183", "DOI": "10.1038/sj.bmt.1705226", "volume": "37", "author": "N Kroger", "year": "2006", "unstructured": "Kroger N, Brand R, van Biezen A, Cahn J-Y, Slavin S, Blaise D et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2006; 37: 183\u2013189.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt200928_CR32", "doi-asserted-by": "publisher", "first-page": "620", "DOI": "10.1046/j.1365-2141.2000.02200.x", "volume": "110", "author": "T de Witte", "year": "2000", "unstructured": "de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the chronic leukaemia working party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2000; 110: 620\u2013630.", "journal-title": "Br J Haematol"}, {"key": "BFbmt200928_CR33", "doi-asserted-by": "publisher", "first-page": "1945", "DOI": "10.1038/sj.leu.2404774", "volume": "21", "author": "HK Al-Ali", "year": "2007", "unstructured": "Al-Ali HK, Brand R, van Biezen A, Finke J, Boogaerts M, Fauser AA et al. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2007; 21: 1945\u20131951.", "journal-title": "Leukemia"}, {"key": "BFbmt200928_CR34", "first-page": "1188", "volume": "95", "author": "HJ Deeg", "year": "2000", "unstructured": "Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000; 95: 1188\u20131194.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR35", "doi-asserted-by": "publisher", "first-page": "963", "DOI": "10.1200/JCO.2000.18.5.963", "volume": "18", "author": "I Yakoub-Agha", "year": "2000", "unstructured": "Yakoub-Agha I, de La Salmoniere P, Ribaud P, Sutton L, Wattel E, Kuentz M et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients\u2014Report of the French Society of Bone Marrow Transplantation. J Clin Oncol 2000; 18: 963\u2013971.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt200928_CR36", "doi-asserted-by": "publisher", "first-page": "227", "DOI": "10.1002/ajh.1121", "volume": "67", "author": "S Bibawi", "year": "2001", "unstructured": "Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol 2001; 67: 227\u2013233.", "journal-title": "Am J Hematol"}, {"key": "BFbmt200928_CR37", "doi-asserted-by": "publisher", "first-page": "1878", "DOI": "10.1038/sj.leu.2402296", "volume": "15", "author": "T de Witte", "year": "2001", "unstructured": "de Witte T, Pikkemaat F, Hermans J, van Biezen A, Mackinnan S, Cornelissen J et al. Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. Leukemia 2001; 15: 1878\u20131884.", "journal-title": "Leukemia"}, {"key": "BFbmt200928_CR38", "doi-asserted-by": "publisher", "first-page": "161", "DOI": "10.1053/bbmt.2002.v8.pm11939606", "volume": "8", "author": "M Jurado", "year": "2002", "unstructured": "Jurado M, Deeg HJ, Storer B, Anasetti C, Anderson JE, Bryant E et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 2002; 8: 161\u2013169.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt200928_CR39", "first-page": "1997", "volume": "100", "author": "J Sierra", "year": "2002", "unstructured": "Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997\u20132004.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR40", "doi-asserted-by": "publisher", "first-page": "667", "DOI": "10.1038/sj.bmt.1705122", "volume": "36", "author": "R Kojima", "year": "2005", "unstructured": "Kojima R, Kami M, Kanda Y, Kusumi E, Kishi Y, Tanaka Y et al. Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transplant 2005; 36: 667\u2013674.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt200928_CR41", "doi-asserted-by": "publisher", "first-page": "619", "DOI": "10.1016/j.bbmt.2005.05.004", "volume": "11", "author": "SR Solomon", "year": "2005", "unstructured": "Solomon SR, Savani BN, Childs R, Montero A, Boss C, Read EJ et al. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome. Biol Blood Marrow Transplant 2005; 11: 619\u2013626.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt200928_CR42", "doi-asserted-by": "publisher", "first-page": "108", "DOI": "10.1016/j.bbmt.2004.10.008", "volume": "11", "author": "R Wong", "year": "2005", "unstructured": "Wong R, Shahjahan M, Wang X, Thall PF, de Lima M, Khouri I et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2005; 11: 108\u2013114.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt200928_CR43", "doi-asserted-by": "publisher", "first-page": "1047", "DOI": "10.1016/j.bbmt.2006.06.003", "volume": "12", "author": "EP Alyea", "year": "2006", "unstructured": "Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12: 1047\u20131055.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt200928_CR44", "doi-asserted-by": "publisher", "first-page": "836", "DOI": "10.1182/blood-2005-11-4503", "volume": "108", "author": "R Martino", "year": "2006", "unstructured": "Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836\u2013846.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR45", "doi-asserted-by": "publisher", "first-page": "128", "DOI": "10.1038/sj.leu.2404010", "volume": "20", "author": "BL Scott", "year": "2006", "unstructured": "Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20: 128\u2013135.", "journal-title": "Leukemia"}, {"key": "BFbmt200928_CR46", "doi-asserted-by": "publisher", "first-page": "322", "DOI": "10.1038/sj.leu.2404037", "volume": "20", "author": "A Shimoni", "year": "2006", "unstructured": "Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322\u2013328.", "journal-title": "Leukemia"}, {"key": "BFbmt200928_CR47", "doi-asserted-by": "publisher", "first-page": "5695", "DOI": "10.1200/JCO.2006.08.0952", "volume": "24", "author": "I Yakoub-Agha", "year": "2006", "unstructured": "Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24: 5695\u20135702.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt200928_CR48", "doi-asserted-by": "publisher", "first-page": "1379", "DOI": "10.1182/blood-2007-02-076307", "volume": "110", "author": "CK Chang", "year": "2007", "unstructured": "Chang CK, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: Similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110: 1379\u20131387.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR49", "doi-asserted-by": "publisher", "first-page": "867", "DOI": "10.1002/ajh.20989", "volume": "82", "author": "CM Flynn", "year": "2007", "unstructured": "Flynn CM, Hirsch B, DeFor T, Barker JN, Miller JS, Wagner JE et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 2007; 82: 867\u2013872.", "journal-title": "Am J Hematol"}, {"key": "BFbmt200928_CR50", "doi-asserted-by": "publisher", "first-page": "932", "DOI": "10.1016/j.bbmt.2007.04.004", "volume": "13", "author": "D Maruyama", "year": "2007", "unstructured": "Maruyama D, Fukuda T, Kato R, Yamasaki S, Usui E, Morita-Hoshi Y et al. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with conventional cytoreductive or reduced-intensity regimen. Biol Blood Marrow Transplant 2007; 13: 932\u2013941.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt200928_CR51", "doi-asserted-by": "publisher", "first-page": "33", "DOI": "10.1038/sj.bmt.1705879", "volume": "41", "author": "R Martino", "year": "2008", "unstructured": "Martino R, Valcarcel D, Brunet S, Sureda A, Sierra J . Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant 2008; 41: 33\u201338.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt200928_CR52", "doi-asserted-by": "publisher", "first-page": "659", "DOI": "10.1038/bmt.2008.226", "volume": "42", "author": "TJ Nevill", "year": "2008", "unstructured": "Nevill TJ, Hogge DE, Toze CL, Nantel SH, Power MM, Abou Mourad YR et al. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML. Bone Marrow Transplant 2008; 42: 659\u2013666.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt200928_CR53", "doi-asserted-by": "publisher", "first-page": "2409", "DOI": "10.1080/10428190412331283206", "volume": "45", "author": "B Scott", "year": "2004", "unstructured": "Scott B, Deeg HJ, Storer B, Chauncey T, Petersdorf S, Slattery J et al. Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. Leuk Lymphoma 2004; 45: 2409\u20132417.", "journal-title": "Leuk Lymphoma"}, {"key": "BFbmt200928_CR54", "doi-asserted-by": "publisher", "first-page": "865", "DOI": "10.1182/blood-2003-11-3750", "volume": "104", "author": "M de Lima", "year": "2004", "unstructured": "de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865\u2013872.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR55", "doi-asserted-by": "publisher", "first-page": "753", "DOI": "10.1016/j.bbmt.2003.08.002", "volume": "9", "author": "GW Chan", "year": "2003", "unstructured": "Chan GW, Foss FM, Klein AK, Sprague K, Miller KB . Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 753\u2013759.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt200928_CR56", "doi-asserted-by": "publisher", "first-page": "336", "DOI": "10.1007/s00277-003-0654-9", "volume": "82", "author": "N Kroger", "year": "2003", "unstructured": "Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336\u2013342.", "journal-title": "Ann Hematol"}, {"key": "BFbmt200928_CR57", "doi-asserted-by": "publisher", "first-page": "3060", "DOI": "10.1200/JCO.2003.02.057", "volume": "21", "author": "DC Taussig", "year": "2003", "unstructured": "Taussig DC, Davies AJ, Cavenagh JD, Oakervee H, Syndercombe-Court D, Kelsey S et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol 2003; 21: 3060\u20133065.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt200928_CR58", "doi-asserted-by": "publisher", "first-page": "3052", "DOI": "10.1182/blood-2003-03-0855", "volume": "102", "author": "R Wong", "year": "2003", "unstructured": "Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102: 3052\u20133059.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR59", "doi-asserted-by": "publisher", "first-page": "1616", "DOI": "10.1182/blood-2003-12-4207", "volume": "104", "author": "AYL Ho", "year": "2004", "unstructured": "Ho AYL, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616\u20131623.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR60", "doi-asserted-by": "publisher", "first-page": "85", "DOI": "10.1111/j.1600-0609.2004.00266.x", "volume": "73", "author": "RK Malladi", "year": "2004", "unstructured": "Malladi RK, Peniket AJ, Norton AE, Campbell AJ, Collins GP, Samol J et al. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. Eur J Haematol 2004; 73: 85\u201392.", "journal-title": "Eur J Haematol"}, {"key": "BFbmt200928_CR61", "doi-asserted-by": "publisher", "first-page": "764", "DOI": "10.1016/j.bbmt.2005.06.006", "volume": "11", "author": "V Gupta", "year": "2005", "unstructured": "Gupta V, Daly A, Lipton JH, Hasegawa W, Chun K, Kamel-Reid S et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 2005; 11: 764\u2013772.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt200928_CR62", "doi-asserted-by": "publisher", "first-page": "5675", "DOI": "10.1200/JCO.2005.07.061", "volume": "23", "author": "C Schmid", "year": "2005", "unstructured": "Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H-J . Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675\u20135687.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt200928_CR63", "doi-asserted-by": "publisher", "first-page": "9387", "DOI": "10.1200/JCO.2005.02.0057", "volume": "23", "author": "S Tauro", "year": "2005", "unstructured": "Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease free survival in patient with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387\u20139393.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt200928_CR64", "doi-asserted-by": "publisher", "first-page": "749", "DOI": "10.1016/j.bbmt.2006.03.009", "volume": "12", "author": "CL Hallemeier", "year": "2006", "unstructured": "Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM et al. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550\u2009cGy total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant 2006; 12: 749\u2013757.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt200928_CR65", "doi-asserted-by": "publisher", "first-page": "201", "DOI": "10.1111/j.1365-2141.2006.06272.x", "volume": "135", "author": "ZY Lim", "year": "2006", "unstructured": "Lim ZY, Ho AYL, Ingram W, Kenyon M, Pearce L, Czepulkowski B et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 2006; 135: 201\u2013209.", "journal-title": "Br J Haematol"}, {"key": "BFbmt200928_CR66", "doi-asserted-by": "publisher", "first-page": "517", "DOI": "10.1111/j.1365-2141.2007.06676.x", "volume": "138", "author": "ZY Lim", "year": "2007", "unstructured": "Lim ZY, Pearce L, Ho AYL, Barber L, Ingram W, Usai M et al. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 2007; 138: 517\u2013526.", "journal-title": "Br J Haematol"}, {"key": "BFbmt200928_CR67", "doi-asserted-by": "publisher", "first-page": "843", "DOI": "10.1038/sj.bmt.1705801", "volume": "40", "author": "R Nakamura", "year": "2007", "unstructured": "Nakamura R, Rodriguez R, Palmer J, Stein A, Naing A, Tsai N et al. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Bone Marrow Transplant 2007; 40: 843\u2013850.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt200928_CR68", "doi-asserted-by": "publisher", "first-page": "454", "DOI": "10.1016/j.bbmt.2006.11.024", "volume": "13", "author": "B Oran", "year": "2007", "unstructured": "Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007; 13: 454\u2013462.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt200928_CR69", "doi-asserted-by": "publisher", "first-page": "329", "DOI": "10.1038/sj.bmt.1705730", "volume": "40", "author": "B Strahm", "year": "2007", "unstructured": "Strahm B, Locatelli F, Bader P, Ehlert K, Kremens B, Zintl F et al. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant 2007; 40: 329\u2013333.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt200928_CR70", "doi-asserted-by": "publisher", "first-page": "181", "DOI": "10.1016/j.bbmt.2007.09.017", "volume": "14", "author": "C Huisman", "year": "2008", "unstructured": "Huisman C, Meijer E, Petersen EJ, Lokhorst HM, Verdonck LF . Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years. Biol Blood Marrow Transplant 2008; 14: 181\u2013186.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt200928_CR71", "doi-asserted-by": "crossref", "first-page": "246", "DOI": "10.1016/j.bbmt.2007.11.012", "volume": "14", "author": "GG Laport", "year": "2008", "unstructured": "Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008; 14: 246\u2013255.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt200928_CR72", "doi-asserted-by": "publisher", "first-page": "577", "DOI": "10.1200/JCO.2007.11.1641", "volume": "26", "author": "D Valcarcel", "year": "2008", "unstructured": "Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577\u2013584.", "journal-title": "J Clin Oncol"}, {"key": "BFbmt200928_CR73", "doi-asserted-by": "publisher", "first-page": "415", "DOI": "10.1182/blood-2007-08-104745", "volume": "112", "author": "R Marks", "year": "2008", "unstructured": "Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 2008; 112: 415\u2013425.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR74", "doi-asserted-by": "publisher", "first-page": "2265", "DOI": "10.1056/NEJMoa041276", "volume": "351", "author": "MJ Laughlin", "year": "2004", "unstructured": "Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang M-J, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265\u20132275.", "journal-title": "N Engl J Med"}, {"key": "BFbmt200928_CR75", "doi-asserted-by": "publisher", "first-page": "4711", "DOI": "10.1182/blood-2002-12-3917", "volume": "101", "author": "J Ooi", "year": "2003", "unstructured": "Ooi J, Iseki T, Takahashi S, Tomonari A, Ishii K, Takasugi K et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 2003; 101: 4711\u20134713.", "journal-title": "Blood"}, {"key": "BFbmt200928_CR76", "doi-asserted-by": "publisher", "first-page": "282", "DOI": "10.1016/j.bbmt.2007.12.488", "volume": "14", "author": "NS Majhail", "year": "2008", "unstructured": "Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M . Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant 2008; 14: 282\u2013289.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt200928_CR77", "doi-asserted-by": "publisher", "first-page": "672", "DOI": "10.1016/j.bbmt.2008.03.009", "volume": "14", "author": "BS Andersson", "year": "2008", "unstructured": "Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M et al. Once daily IV busulfan and fludarabine (IV Bu-Flu) compares favorably with IV busulfan and cyclophosphamide (IV BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008; 14: 672\u2013684.", "journal-title": "Biol Blood Marrow Transplant"}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bmt200928.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt200928", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt200928.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 13]], "date-time": "2019-04-13T14:04:41Z", "timestamp": 1555164281000}, "score": 25.364695, "issued": {"date-parts": [[2009, 3, 2]]}, "references-count": 77, "journal-issue": {"published-print": {"date-parts": [[2009, 4]]}, "issue": "8"}, "alternative-id": ["BFbmt200928"], "URL": "http://dx.doi.org/10.1038/bmt.2009.28", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T07:32:45Z", "timestamp": 1575185565977}, "reference-count": 40, "publisher": "Springer Science and Business Media LLC", "issue": "S1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2005, 11, 5]], "date-time": "2005-11-05T00:00:00Z", "timestamp": 1131148800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Ann Hematol"], "published-print": {"date-parts": [[2005, 12]]}, "DOI": "10.1007/s00277-005-0019-7", "type": "journal-article", "created": {"date-parts": [[2005, 11, 4]], "date-time": "2005-11-04T16:02:08Z", "timestamp": 1131120128000}, "page": "18-24", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Clinical experience with decitabine in North American patients with myelodysplastic syndrome"], "prefix": "10.1007", "volume": "84", "author": [{"given": "Karen W. L.", "family": "Yee", "sequence": "first", "affiliation": []}, {"given": "Elias", "family": "Jabbour", "sequence": "additional", "affiliation": []}, {"given": "Hagop M.", "family": "Kantarjian", "sequence": "additional", "affiliation": []}, {"given": "Francis J.", "family": "Giles", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2005, 11, 5]]}, "reference": [{"key": "19_CR1", "first-page": "138a", "volume": "104", "author": "A Aggerholm", "year": "2004", "unstructured": "Aggerholm A, Holm MS, Guldberg P, Hokland P (2004) Delineation of promoter methylation in patients with myelodysplastic syndromes: widespread and concurrent hypermethylation of multiple genes and increased mRNA expression of the DNA methyltransferases DNMT1, 3A and 3B. Blood 104:138a (Abstract 472)", "journal-title": "Blood"}, {"key": "19_CR2", "doi-asserted-by": "crossref", "first-page": "1903", "DOI": "10.1038/sj.leu.2403046", "volume": "17", "author": "E Aoki", "year": "2003", "unstructured": "Aoki E, Ohashi H, Uchida T, Murate T, Saito H, Kinoshita T (2003) Expression levels of DNA methyltransferase genes do not correlate with p15INK4B gene methylation in myelodysplastic syndromes. Leukemia 17:1903\u20131904", "journal-title": "Leukemia"}, {"key": "19_CR3", "doi-asserted-by": "crossref", "first-page": "189", "DOI": "10.1111/j.1365-2141.1982.tb08475.x", "volume": "51", "author": "JM Bennett", "year": "1982", "unstructured": "Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189\u2013199", "journal-title": "Br J Haematol"}, {"key": "19_CR4", "doi-asserted-by": "crossref", "first-page": "103", "DOI": "10.1038/5047", "volume": "21", "author": "EE Cameron", "year": "1999", "unstructured": "Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103\u2013110", "journal-title": "Nat Genet"}, {"key": "19_CR5", "doi-asserted-by": "crossref", "first-page": "1813", "DOI": "10.1038/sj.leu.2403054", "volume": "17", "author": "DH Christiansen", "year": "2003", "unstructured": "Christiansen DH, Andersen MK, Pedersen-Bjergaard J (2003) Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 17:1813\u20131819", "journal-title": "Leukemia"}, {"key": "19_CR6", "doi-asserted-by": "crossref", "first-page": "132", "DOI": "10.1038/72785", "volume": "24", "author": "JF Costello", "year": "2000", "unstructured": "Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C (2000) Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nat Genet 24:132\u2013138", "journal-title": "Nat Genet"}, {"key": "19_CR7", "first-page": "2041", "volume": "257", "author": "F Creusot", "year": "1982", "unstructured": "Creusot F, Acs G, Christman JK (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5\u2032-azacytidine and 5\u2032-aza-2\u2032-deoxycytidine. J Biol Chem 257:2041\u20132048", "journal-title": "J Biol Chem"}, {"key": "19_CR8", "doi-asserted-by": "crossref", "first-page": "2957", "DOI": "10.1182/blood.V100.8.2957", "volume": "100", "author": "M Daskalakis", "year": "2002", "unstructured": "Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P, Jones PA, Lubbert M (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2\u2032-deoxycytidine (decitabine) treatment. Blood 100:2957\u20132964", "journal-title": "Blood"}, {"key": "19_CR9", "first-page": "3225", "volume": "61", "author": "M Esteller", "year": "2001", "unstructured": "Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225\u20133229", "journal-title": "Cancer Res"}, {"key": "19_CR10", "doi-asserted-by": "crossref", "first-page": "571s", "DOI": "10.1200/jco.2005.23.16_suppl.6544", "volume": "23", "author": "G Garcia-Manero", "year": "2005", "unstructured": "Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Verstovsek S, Ravandi F, Rytting M, Cortes J, Yang H, Fiorentino J, Rosner G, Issa J-P (2005) Results of a phase I/II study of the combination of 5-aza-2\u2032-deoxycytidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23:571s (Abstract 6544)", "journal-title": "J Clin Oncol"}, {"key": "19_CR11", "doi-asserted-by": "crossref", "first-page": "489", "DOI": "10.1126/science.1083558", "volume": "300", "author": "F Gaudet", "year": "2003", "unstructured": "Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R (2003) Induction of tumors in mice by genomic hypomethylation. Science 300:489\u2013492", "journal-title": "Science"}, {"key": "19_CR12", "first-page": "2079", "volume": "89", "author": "P Greenberg", "year": "1977", "unstructured": "Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1977) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079\u20132088", "journal-title": "Blood"}, {"key": "19_CR13", "doi-asserted-by": "crossref", "first-page": "1635", "DOI": "10.1182/blood-2003-03-0687", "volume": "103", "author": "JP Issa", "year": "2004", "unstructured": "Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635\u20131640", "journal-title": "Blood"}, {"key": "19_CR14", "doi-asserted-by": "crossref", "first-page": "85", "DOI": "10.1016/0092-8674(80)90237-8", "volume": "20", "author": "PA Jones", "year": "1980", "unstructured": "Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85\u201393", "journal-title": "Cell"}, {"key": "19_CR15", "doi-asserted-by": "crossref", "first-page": "402a", "DOI": "10.1182/blood-2004-02-0711", "volume": "104", "author": "HM Kantarjian", "year": "2004", "unstructured": "Kantarjian HM, Ravandi F, O'Brien S, Giles F, Faderl S, Garcia-Manero G, Davis J, Estey E, Issa JP (2004) Decitabine low-dose schedule (100\u00a0mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules. Blood 104:402a (Abstract 1437)", "journal-title": "Blood"}, {"key": "19_CR16", "doi-asserted-by": "crossref", "first-page": "325", "DOI": "10.1016/j.leukres.2004.08.004", "volume": "29", "author": "F Langer", "year": "2005", "unstructured": "Langer F, Dingemann J, Kreipe H, Lehmann U (2005) Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leuk Res 29:325\u2013329", "journal-title": "Leuk Res"}, {"key": "19_CR17", "doi-asserted-by": "crossref", "first-page": "442", "DOI": "10.1126/science.1084468", "volume": "300", "author": "C Lengauer", "year": "2003", "unstructured": "Lengauer C (2003) An unstable liaison. Science 300:442\u2013443", "journal-title": "Science"}, {"key": "19_CR18", "doi-asserted-by": "crossref", "first-page": "751", "DOI": "10.1016/0145-2126(90)90067-J", "volume": "14", "author": "RL Momparler", "year": "1990", "unstructured": "Momparler RL, Lalibert\u00e9 J (1990) Induction of cytidine deaminase in HL-60 myeloid leukemia cells by 5-aza-2\u2032-deoxycytidine. Leuk Res 14:751\u2013754", "journal-title": "Leuk Res"}, {"key": "19_CR19", "first-page": "571s", "volume": "3", "author": "S O'Brien", "year": "2005", "unstructured": "O'Brien S, Issa J-P, Ravandi-Kashani F, Giles F, Faderl S, Garcia-Manero G, Davis J, Estey E, Kantarjian H (2005) Decitabine low-dose schedule (100\u00a0mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules. J Clin Oncol 23:571s (Abstract 6545)", "journal-title": "J Clin Oncol"}, {"key": "19_CR20", "doi-asserted-by": "crossref", "first-page": "571s", "DOI": "10.1200/jco.2005.23.16_suppl.571", "volume": "23", "author": "Y Oki", "year": "2005", "unstructured": "Oki Y, Kantarjian H, Davis J, Ravandi-Kashani F, Verstovsek S, Cortes JE, Garcia-Manero G, Issa J-P (2005) Hypomethylation induction in MDS after treatment with decitabine at three different doses. J Clin Oncol 23:571s (Abstract 6548)", "journal-title": "J Clin Oncol"}, {"key": "19_CR21", "first-page": "1114", "volume": "63", "author": "MF Paz", "year": "2003", "unstructured": "Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M (2003) A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63:1114\u20131121", "journal-title": "Cancer Res"}, {"issue": "Suppl 3", "key": "19_CR22", "first-page": "28", "volume": "4", "author": "A Pinto", "year": "1989", "unstructured": "Pinto A, Zagonel V, Attadia V, Bullian PL, Gattei V, Carbone A, Monfardini S, Colombatti A (1989) 5-Aza-2\u2032-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 4(Suppl 3):28\u201332", "journal-title": "Bone Marrow Transplant"}, {"key": "19_CR23", "first-page": "2985", "volume": "91", "author": "B Quesnel", "year": "1998", "unstructured": "Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M, Fenaux P (1998) Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985\u20132990", "journal-title": "Blood"}, {"key": "19_CR24", "first-page": "651a", "volume": "104", "author": "K Raj", "year": "2004", "unstructured": "Raj K, John A, Ho A, Thomas NSB, Mufti GJ (2004) 5-Azacytidine in the treatment of high risk myelodysplastic syndromes: clinical response can occur without demethylation of the CDKN2B, CDKN1A or TP73 gene promoters. Blood 104:651a (Abstract 2369)", "journal-title": "Blood"}, {"key": "19_CR25", "first-page": "23a", "volume": "104", "author": "H Saba", "year": "2004", "unstructured": "Saba H, Rosenfeld C, Issa JP, DiPersio J, Raza A, Klimek V, Slack J, de Castro C, Mettinger K, Kantarjian HM (2004) First report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS). Blood 104:23a (Abstract 67)", "journal-title": "Blood"}, {"key": "19_CR26", "doi-asserted-by": "crossref", "first-page": "570s", "DOI": "10.1200/jco.2005.23.16_suppl.570", "volume": "23", "author": "HI Saba", "year": "2005", "unstructured": "Saba HI, Rosenfeld CS, Issa J-P, Bennett JM, Decastro C, Dipersio J, Kantarjian H (2005) Clinical benefit and survival endpoints from a phase III trial comparing decitabine (DAC) vs supportive care (SC) in patients with advanced myelodysplastic syndromes (MDS). J Clin Oncol 23:570s (Abstract 6543)", "journal-title": "J Clin Oncol"}, {"key": "19_CR27", "doi-asserted-by": "crossref", "first-page": "103", "DOI": "10.1038/sj.leu.2403552", "volume": "19", "author": "K Schmelz", "year": "2005", "unstructured": "Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I (2005) Induction of gene expression by 5-Aza-2\u2032-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 19:103\u2013111", "journal-title": "Leukemia"}, {"key": "19_CR28", "first-page": "3212", "volume": "62", "author": "H Shi", "year": "2002", "unstructured": "Shi H, Yan PS, Chen CM, Rahmatpanah F, Lofton-Day C, Caldwell CW, Huang TH (2002) Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer Res 62:3212\u20133220", "journal-title": "Cancer Res"}, {"key": "19_CR29", "doi-asserted-by": "crossref", "first-page": "2429", "DOI": "10.1200/JCO.2002.04.117", "volume": "20", "author": "LR Silverman", "year": "2002", "unstructured": "Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429\u20132440", "journal-title": "J Clin Oncol"}, {"key": "19_CR30", "doi-asserted-by": "crossref", "first-page": "148", "DOI": "10.1046/j.1365-2141.2001.02496.x", "volume": "112", "author": "HF Tien", "year": "2001", "unstructured": "Tien HF, Tang JH, Tsay W, Liu MC, Lee FY, Wang CH, Chen YC, Shen MC (2001) Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 112:148\u2013154", "journal-title": "Br J Haematol"}, {"key": "19_CR31", "first-page": "1403", "volume": "90", "author": "T Uchida", "year": "1997", "unstructured": "Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T, Murate T (1997) Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 90:1403\u20131409", "journal-title": "Blood"}, {"key": "19_CR32", "first-page": "1995", "volume": "28", "author": "J Vesely", "year": "1968", "unstructured": "Vesely J, Cihak A, Sorm F (1968) Characteristics of mouse leukemic cells resistant to 5-azacytidine and 5-aza-2\u2032-deoxycytidine. Cancer Res 28:1995\u20132000", "journal-title": "Cancer Res"}, {"key": "19_CR33", "first-page": "2180", "volume": "30", "author": "J Vesely", "year": "1970", "unstructured": "Vesely J, Cihak A, Sorm F (1970) Association of decreased uridine and deoxycytidine kinase with enhanced RNA and DNA polymerase in mouse leukemic cells resistant to 5-azacytidine and 5-aza-2\u2032-deoxycytidine. Cancer Res 30:2180\u20132186", "journal-title": "Cancer Res"}, {"issue": "Suppl 1", "key": "19_CR34", "first-page": "19", "volume": "11", "author": "PW Wijermans", "year": "1997", "unstructured": "Wijermans PW, Krulder JWM, Huijgens PC, Neve P (1997) Continuous infusion of low-dose 5-Aza-2\u2032-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11(Suppl 1):19\u201323", "journal-title": "Leukemia"}, {"key": "19_CR35", "doi-asserted-by": "crossref", "first-page": "956", "DOI": "10.1200/JCO.2000.18.5.956", "volume": "18", "author": "P Wijermans", "year": "2000", "unstructured": "Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-aza-2\u2032-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18:956\u2013962", "journal-title": "J Clin Oncol"}, {"key": "19_CR36", "doi-asserted-by": "crossref", "first-page": "96a", "DOI": "10.1182/blood.V100.1.96", "volume": "100", "author": "PW Wijermans", "year": "2002", "unstructured": "Wijermans PW, Luebbert M, Verhoef G (2002) Low dose decitabine for elderly high risk MDS patients: who will respond? Blood 100:96a (Abstract 355)", "journal-title": "Blood"}, {"key": "19_CR37", "first-page": "3493", "volume": "43", "author": "VL Wilson", "year": "1983", "unstructured": "Wilson VL, Jones PA, Momparler RL (1983) Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2\u2032-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 43:3493\u20133496", "journal-title": "Cancer Res"}, {"key": "19_CR38", "doi-asserted-by": "crossref", "first-page": "1153b", "DOI": "10.1126/science.1089523", "volume": "302", "author": "AS Yang", "year": "2003", "unstructured": "Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP (2003) Comment on \u201cChromosomal instability and tumors promoted by DNA hypomethylation\u201d and \u201cInduction of tumors in mice by genomic hypomethylation.\u201d Science 302:1153b", "journal-title": "Science"}, {"key": "19_CR39", "first-page": "622a", "volume": "102", "author": "H Yang", "year": "2003", "unstructured": "Yang H, Hoshino K, Canalli AA, Sanchez-Gonzalez B, Kantarjian H, Issa J-P, Garcia-Manero G (2003) Preclinical studies of the combination of the hypomethylating agent 5-aza-2\u2032deoxycytidine (decitabine) and the histone deacetylase inhibitor (HDI) valproic acid (VPA) in leukemic cell systems. Blood 102:622a (Abstract 2295)", "journal-title": "Blood"}, {"issue": "Suppl 1", "key": "19_CR40", "first-page": "30", "volume": "7", "author": "V Zagonel", "year": "1993", "unstructured": "Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, De Angelis V, Monfardini S, Pinto A (1993) 5-Aza-2\u2032-deoxycytidine (decitabine) induces trilineage response in infavorable myelodysplastic syndromes. Leukemia 7(Suppl 1):30\u201335", "journal-title": "Leukemia"}], "container-title": ["Annals of Hematology"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s00277-005-0019-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s00277-005-0019-7/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s00277-005-0019-7", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 28]], "date-time": "2019-05-28T09:44:49Z", "timestamp": 1559036689000}, "score": 24.988817, "issued": {"date-parts": [[2005, 11, 5]]}, "references-count": 40, "journal-issue": {"published-print": {"date-parts": [[2005, 12]]}, "issue": "S1"}, "alternative-id": ["19"], "URL": "http://dx.doi.org/10.1007/s00277-005-0019-7", "relation": {"cites": []}, "ISSN": ["0939-5555", "1432-0584"], "issn-type": [{"value": "0939-5555", "type": "print"}, {"value": "1432-0584", "type": "electronic"}], "subject": ["Hematology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T04:17:40Z", "timestamp": 1574223460875}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2006, 9, 1]], "date-time": "2006-09-01T00:00:00Z", "timestamp": 1157068800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Neurophysiology"], "published-print": {"date-parts": [[2006, 9]]}, "DOI": "10.1016/j.clinph.2006.07.100", "type": "journal-article", "created": {"date-parts": [[2006, 7, 30]], "date-time": "2006-07-30T06:37:50Z", "timestamp": 1154241470000}, "page": "34", "source": "Crossref", "is-referenced-by-count": 0, "title": ["BS15 Carpal tunnel syndrome"], "prefix": "10.1016", "volume": "117", "author": [{"given": "L.", "family": "Padua", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Clinical Neurophysiology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1388245706010935?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1388245706010935?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 14]], "date-time": "2019-01-14T18:20:16Z", "timestamp": 1547490016000}, "score": 24.752693, "issued": {"date-parts": [[2006, 9]]}, "references-count": 0, "alternative-id": ["S1388245706010935"], "URL": "http://dx.doi.org/10.1016/j.clinph.2006.07.100", "ISSN": ["1388-2457"], "issn-type": [{"value": "1388-2457", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T11:57:57Z", "timestamp": 1574510277288}, "reference-count": 19, "publisher": "Springer Science and Business Media LLC", "issue": "5", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2012, 10, 15]], "date-time": "2012-10-15T00:00:00Z", "timestamp": 1350259200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2013, 5]]}, "DOI": "10.1038/bmt.2012.197", "type": "journal-article", "created": {"date-parts": [[2012, 10, 15]], "date-time": "2012-10-15T11:11:18Z", "timestamp": 1350299478000}, "page": "703-707", "source": "Crossref", "is-referenced-by-count": 17, "title": ["Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT"], "prefix": "10.1038", "volume": "48", "author": [{"given": "A M", "family": "Holm", "sequence": "first", "affiliation": []}, {"given": "G C", "family": "Riise", "sequence": "additional", "affiliation": []}, {"given": "L", "family": "Hansson", "sequence": "additional", "affiliation": []}, {"given": "L", "family": "Brinch", "sequence": "additional", "affiliation": []}, {"given": "\u00d8", "family": "Bj\u00f8rtuft", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Iversen", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Simonsen", "sequence": "additional", "affiliation": []}, {"given": "Y", "family": "Fl\u00f8isand", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 10, 15]]}, "reference": [{"key": "BFbmt2012197_CR1", "doi-asserted-by": "publisher", "first-page": "945", "DOI": "10.1016/j.bbmt.2005.09.004", "volume": "11", "author": "AH Filipovich", "year": "2005", "unstructured": "Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt2012197_CR2", "doi-asserted-by": "publisher", "first-page": "426", "DOI": "10.1097/01.moh.0000245689.47333.ff", "volume": "13", "author": "K Baird", "year": "2006", "unstructured": "Baird K, Pavletic SZ . Chronic graft versus host disease. Curr Op Hematol 2006; 13: 426\u2013435.", "journal-title": "Curr Op Hematol"}, {"key": "BFbmt2012197_CR3", "doi-asserted-by": "publisher", "first-page": "337", "DOI": "10.1038/bmt.2012.5", "volume": "47", "author": "NS Majhail", "year": "2012", "unstructured": "Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 337\u2013341.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012197_CR4", "doi-asserted-by": "publisher", "first-page": "4236", "DOI": "10.1182/blood-2002-10-3289", "volume": "102", "author": "E Sakaida", "year": "2003", "unstructured": "Sakaida E, Nakaseko C, Harima A, Yokota A, Cho R, Saito Y et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood 2003; 102: 4236\u20134242.", "journal-title": "Blood"}, {"key": "BFbmt2012197_CR5", "doi-asserted-by": "publisher", "first-page": "901", "DOI": "10.1183/09031936.04.00084804", "volume": "23", "author": "MB Lund", "year": "2004", "unstructured": "Lund MB, Brinch L, Kongerud J, Boe J . Lung function 5 yrs after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide. Eur Resp J 2004; 23: 901\u2013905.", "journal-title": "Eur Resp J"}, {"key": "BFbmt2012197_CR6", "doi-asserted-by": "publisher", "first-page": "1358", "DOI": "10.1016/j.healun.2010.05.023", "volume": "29", "author": "R Vos", "year": "2010", "unstructured": "Vos R, Vanaudenaerde BM, Ottevaere A, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: Divide and conquer? J Heart Lung Transplant 2010; 29: 1358\u20131368.", "journal-title": "J Heart Lung Transplant"}, {"issue": "1 Suppl", "key": "BFbmt2012197_CR7", "doi-asserted-by": "publisher", "first-page": "S106", "DOI": "10.1016/j.bbmt.2009.11.002", "volume": "16", "author": "JW Chien", "year": "2010", "unstructured": "Chien JW, Duncan S, Williams KM, Pavletic SZ . Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16 (1 Suppl): S106\u2013S114.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt2012197_CR8", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1038/bmt.2011.38", "volume": "47", "author": "PJ Martin", "year": "2012", "unstructured": "Martin PJ, Chien JW . What we know and mostly do not know about bronchiolitis obliterans syndrome. Bone Marrow Transplant 2012; 47: 1\u20134.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012197_CR9", "doi-asserted-by": "publisher", "first-page": "426", "DOI": "10.1038/bmt.2010.152", "volume": "46", "author": "CE Lucid", "year": "2011", "unstructured": "Lucid CE, Savani BN, Engelhardt BG, Shah P, Clifton C, Greenhut SL et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant 2011; 46: 426\u2013429.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012197_CR10", "doi-asserted-by": "publisher", "first-page": "3023", "DOI": "10.1016/j.transproceed.2010.07.086", "volume": "42", "author": "J Redel-Montero", "year": "2010", "unstructured": "Redel-Montero J, Bujalance-Cabrera C, Vaquero-Barrios J-M, Santos-Luna F, Arenas-De Larriva M, Moreno-Casado P et al. Lung transplantation for bronchiolitis obliterans after allogenic bone marrow transplantation. Transplant Proc 2010; 42: 3023\u20133025.", "journal-title": "Transplant Proc"}, {"key": "BFbmt2012197_CR11", "doi-asserted-by": "publisher", "first-page": "1341", "DOI": "10.1097/00007890-200105150-00028", "volume": "71", "author": "W Rabitsch", "year": "2001", "unstructured": "Rabitsch W, Deviatko E, Keil F, Herold C, Dekan G, Greinix HT et al. Successful lung transplantation for bronchiolitis obliterans after allogeneic marrow transplantation. Transplantation 2001; 71: 1341\u20131343.", "journal-title": "Transplantation"}, {"key": "BFbmt2012197_CR12", "doi-asserted-by": "publisher", "first-page": "254", "DOI": "10.1111/j.1399-0012.2011.01482.x", "volume": "26", "author": "BA Whitson", "year": "2012", "unstructured": "Whitson BA, Shelstad RC, Hertz MI, Kelly RF, D\u2019aposCunha J, Shumway SJ . Lung transplantation after hematopoietic stem cell transplantation. Clin Transplant 2012; 26: 254\u2013258.", "journal-title": "Clin Transplant"}, {"key": "BFbmt2012197_CR13", "doi-asserted-by": "publisher", "first-page": "633", "DOI": "10.1038/sj.bmt.1703952", "volume": "31", "author": "KY Chiang", "year": "2003", "unstructured": "Chiang KY, Lazarus HM . Should we be performing more combined hematopoietic stem cell plus solid organ transplants? Bone Marrow Transplant 2003; 31: 633\u2013642.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012197_CR14", "doi-asserted-by": "publisher", "first-page": "1104", "DOI": "10.1016/j.healun.2011.08.004", "volume": "30", "author": "JD Christie", "year": "2011", "unstructured": "Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report\u20142011. J Heart Lung Transplant 2011; 30: 1104\u20131122.", "journal-title": "J Heart Lung Transplant"}, {"key": "BFbmt2012197_CR15", "doi-asserted-by": "publisher", "first-page": "1897", "DOI": "10.1111/j.1600-6143.2010.03187.x", "volume": "10", "author": "C Koenecke", "year": "2010", "unstructured": "Koenecke C, Hertenstein B, Schetelig J, Van Biezen A, Dammann E, Gratwohl A et al. Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: a retrospective, multicenter study of the EBMT. Am J Transplant 2010; 10: 1897\u20131906.", "journal-title": "Am J Transplant"}, {"key": "BFbmt2012197_CR16", "doi-asserted-by": "publisher", "first-page": "745", "DOI": "10.1016/j.healun.2006.03.011", "volume": "25", "author": "J Orens", "year": "2006", "unstructured": "Orens J, Estenne M, Arcasoy S, Conte J, Corris P, Egan J et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745\u2013755.", "journal-title": "J Heart Lung Transplant"}, {"key": "BFbmt2012197_CR17", "doi-asserted-by": "publisher", "first-page": "5084", "DOI": "10.1182/blood-2011-07-365817", "volume": "118", "author": "C Ustun", "year": "2011", "unstructured": "Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR . Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 2011; 118: 5084\u20135095.", "journal-title": "Blood"}, {"key": "BFbmt2012197_CR18", "doi-asserted-by": "publisher", "first-page": "761", "DOI": "10.7326/0003-4819-152-12-201006150-00003", "volume": "152", "author": "SM Palmer", "year": "2010", "unstructured": "Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152: 761\u2013769.", "journal-title": "Ann Intern Med"}, {"key": "BFbmt2012197_CR19", "doi-asserted-by": "publisher", "first-page": "1143", "DOI": "10.1016/j.bbmt.2009.06.019", "volume": "15", "author": "M Tomblyn", "year": "2009", "unstructured": "Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143\u20131238.", "journal-title": "Biol Blood Marrow Transplant"}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bmt2012197.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt2012197", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt2012197.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 13]], "date-time": "2019-04-13T14:06:54Z", "timestamp": 1555164414000}, "score": 24.616346, "issued": {"date-parts": [[2012, 10, 15]]}, "references-count": 19, "journal-issue": {"published-print": {"date-parts": [[2013, 5]]}, "issue": "5"}, "alternative-id": ["BFbmt2012197"], "URL": "http://dx.doi.org/10.1038/bmt.2012.197", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T03:28:53Z", "timestamp": 1574566133136}, "reference-count": 28, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2014, 9, 1]], "date-time": "2014-09-01T00:00:00Z", "timestamp": 1409529600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["clinical-lymphoma-myeloma-leukemia.com", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Clinical Lymphoma Myeloma and Leukemia"], "published-print": {"date-parts": [[2014, 9]]}, "DOI": "10.1016/j.clml.2014.06.015", "type": "journal-article", "created": {"date-parts": [[2014, 12, 5]], "date-time": "2014-12-05T23:24:35Z", "timestamp": 1417821875000}, "page": "S42-S45", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Should Patients With High-Risk or Transformed Myelodysplastic Syndrome Proceed Directly to\u00a0Allogeneic Transplant Without Prior Cytoreduction by Remission-Induction Chemotherapy or Hypomethylating Agent\u00a0Therapy?"], "prefix": "10.1016", "volume": "14", "author": [{"given": "Theo M.", "family": "de Witte", "sequence": "first", "affiliation": []}, {"given": "David", "family": "Bowen", "sequence": "additional", "affiliation": []}, {"given": "Marie", "family": "Robin", "sequence": "additional", "affiliation": []}, {"given": "Luca", "family": "Malcovati", "sequence": "additional", "affiliation": []}, {"given": "Ghulam", "family": "Mufti", "sequence": "additional", "affiliation": []}, {"given": "Dietger", "family": "Niederwieser", "sequence": "additional", "affiliation": []}, {"given": "Ibrahim", "family": "Yakoubagha", "sequence": "additional", "affiliation": []}, {"given": "Nicolaus", "family": "Kr\u00f6ger", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Lymphoma Myeloma and Leukemia"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S2152265014001700?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S2152265014001700?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 9, 27]], "date-time": "2018-09-27T05:56:31Z", "timestamp": 1538027791000}, "score": 24.296661, "issued": {"date-parts": [[2014, 9]]}, "references-count": 28, "alternative-id": ["S2152265014001700"], "URL": "http://dx.doi.org/10.1016/j.clml.2014.06.015", "ISSN": ["2152-2650"], "issn-type": [{"value": "2152-2650", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Should Patients With High-Risk or Transformed Myelodysplastic Syndrome Proceed Directly to\u00a0Allogeneic Transplant Without Prior Cytoreduction by Remission-Induction Chemotherapy or Hypomethylating Agent\u00a0Therapy?", "name": "articletitle", "label": "Article Title"}, {"value": "Clinical Lymphoma Myeloma and Leukemia", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.clml.2014.06.015", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2014 Elsevier Inc. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T14:27:21Z", "timestamp": 1574778441044}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2017, 4, 1]], "date-time": "2017-04-01T00:00:00Z", "timestamp": 1491004800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia Research"], "published-print": {"date-parts": [[2017, 4]]}, "DOI": "10.1016/s0145-2126(17)30207-2", "type": "journal-article", "created": {"date-parts": [[2017, 5, 3]], "date-time": "2017-05-03T08:53:54Z", "timestamp": 1493801634000}, "page": "S58-S59", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Evaluation of Salvage Induction Chemotherapy Regimens in Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure"], "prefix": "10.1016", "volume": "55", "author": [{"given": "B.", "family": "Ball", "sequence": "first", "affiliation": []}, {"given": "R.", "family": "Komrokji", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Ad\u00e8s", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Sekeres", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "DeZern", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Pleyer", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "Vey", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Almeida", "sequence": "additional", "affiliation": []}, {"given": "U.", "family": "Germing", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Cluzeau", "sequence": "additional", "affiliation": []}, {"given": "U.", "family": "Platzbecker", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Gore", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Fenaux", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Prebet", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Leukemia Research"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0145212617302072?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0145212617302072?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 9, 2]], "date-time": "2018-09-02T05:25:25Z", "timestamp": 1535865925000}, "score": 24.174068, "issued": {"date-parts": [[2017, 4]]}, "references-count": 0, "alternative-id": ["S0145212617302072"], "URL": "http://dx.doi.org/10.1016/s0145-2126(17)30207-2", "ISSN": ["0145-2126"], "issn-type": [{"value": "0145-2126", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T01:10:34Z", "timestamp": 1574298634119}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2009, 5, 1]], "date-time": "2009-05-01T00:00:00Z", "timestamp": 1241136000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia Research"], "published-print": {"date-parts": [[2009, 5]]}, "DOI": "10.1016/s0145-2126(09)70176-6", "type": "journal-article", "created": {"date-parts": [[2009, 5, 4]], "date-time": "2009-05-04T08:39:08Z", "timestamp": 1241426348000}, "page": "S115", "source": "Crossref", "is-referenced-by-count": 0, "title": ["P096 Varicella-zoster virus meningoencephalitis during the course of hypomethylating agent therapy in high risk myelodysplastic syndrome"], "prefix": "10.1016", "volume": "33", "author": [{"given": "T.", "family": "Challan-Belval", "sequence": "first", "affiliation": []}, {"given": "S.", "family": "Reutenauer", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Martin-Blondel", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Sorin", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Laurent", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Adoue", "sequence": "additional", "affiliation": []}, {"given": "O.", "family": "Beyne-Rauzy", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Leukemia Research"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0145212609701766?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0145212609701766?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 20]], "date-time": "2018-12-20T05:59:11Z", "timestamp": 1545285551000}, "score": 23.671337, "issued": {"date-parts": [[2009, 5]]}, "references-count": 0, "alternative-id": ["S0145212609701766"], "URL": "http://dx.doi.org/10.1016/s0145-2126(09)70176-6", "ISSN": ["0145-2126"], "issn-type": [{"value": "0145-2126", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T13:35:37Z", "timestamp": 1574516137427}, "reference-count": 18, "publisher": "Springer Science and Business Media LLC", "issue": "6", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2012, 11, 19]], "date-time": "2012-11-19T00:00:00Z", "timestamp": 1353283200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bone Marrow Transplant"], "published-print": {"date-parts": [[2013, 6]]}, "DOI": "10.1038/bmt.2012.228", "type": "journal-article", "created": {"date-parts": [[2012, 11, 19]], "date-time": "2012-11-19T13:31:31Z", "timestamp": 1353331891000}, "page": "814-818", "source": "Crossref", "is-referenced-by-count": 6, "title": ["Chest health surveillance utility in the early detection of bronchiolitis obliterans syndrome in children after allo-SCT"], "prefix": "10.1038", "volume": "48", "author": [{"given": "A", "family": "Gassas", "sequence": "first", "affiliation": []}, {"given": "H", "family": "Craig-Barnes", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Dell", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "Doyle", "sequence": "additional", "affiliation": []}, {"given": "T", "family": "Schechter", "sequence": "additional", "affiliation": []}, {"given": "L", "family": "Sung", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Egeler", "sequence": "additional", "affiliation": []}, {"given": "N", "family": "Palaniyar", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 11, 19]]}, "reference": [{"key": "BFbmt2012228_CR1", "doi-asserted-by": "publisher", "first-page": "S106", "DOI": "10.1016/j.bbmt.2009.11.002", "volume": "16", "author": "JW Chien", "year": "2010", "unstructured": "Chien JW, Duncan S, Williams KM, Pavletic SZ . Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: S106\u2013S114.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt2012228_CR2", "doi-asserted-by": "publisher", "first-page": "193", "DOI": "10.1002/ppul.20145", "volume": "39", "author": "G Kurland", "year": "2005", "unstructured": "Kurland G, Michelson P . Bronchiolitis obliterans in children. Pediatr Pulmonol 2005; 39: 193\u2013208.", "journal-title": "Pediatr Pulmonol"}, {"key": "BFbmt2012228_CR3", "doi-asserted-by": "publisher", "first-page": "466", "DOI": "10.1002/ppul.10097", "volume": "33", "author": "T Mauad", "year": "2002", "unstructured": "Mauad T, Dolhnikoff M . Histology of childhood bronchiolitis obliterans. Pediatr Pulmonol 2002; 33: 466\u2013474.", "journal-title": "Pediatr Pulmonol"}, {"key": "BFbmt2012228_CR4", "doi-asserted-by": "publisher", "first-page": "153", "DOI": "10.1378/chest.128.1.153", "volume": "128", "author": "LH Santo Tomas", "year": "2005", "unstructured": "Santo Tomas LH, Loberiza FR, Klein JP, Layde PM, Lipchik RJ, Rizzo JD et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005; 128: 153\u2013161.", "journal-title": "Chest"}, {"key": "BFbmt2012228_CR5", "doi-asserted-by": "publisher", "first-page": "657", "DOI": "10.1016/S1083-8791(03)00242-8", "volume": "9", "author": "AZ Dudek", "year": "2003", "unstructured": "Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ . Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9: 657\u2013666.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt2012228_CR6", "doi-asserted-by": "publisher", "first-page": "208", "DOI": "10.1164/rccm.200212-1468OC", "volume": "168", "author": "JW Chien", "year": "2003", "unstructured": "Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168: 208\u2013214.", "journal-title": "Am J Respir Crit Care Med"}, {"key": "BFbmt2012228_CR7", "doi-asserted-by": "publisher", "first-page": "393", "DOI": "10.1002/1099-0496(200011)30:5<393::AID-PPUL5>3.0.CO;2-W", "volume": "30", "author": "M Griese", "year": "2000", "unstructured": "Griese M, Rampf U, Hofmann D, Fuhrer M, Reinhardt D, Bender-Gotze C . Pulmonary complications after bone marrow transplantation in children: twenty-four years of experience in a single pediatric center. Pediatr Pulmonol 2000; 30: 393\u2013401.", "journal-title": "Pediatr Pulmonol"}, {"key": "BFbmt2012228_CR8", "doi-asserted-by": "publisher", "first-page": "971", "DOI": "10.1038/bmt.2008.19", "volume": "41", "author": "CN Duncan", "year": "2008", "unstructured": "Duncan CN, Buonanno MR, Barry EV, Myers K, Peritz D, Lehmann L . Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 971\u2013975.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012228_CR9", "doi-asserted-by": "publisher", "first-page": "135", "DOI": "10.1038/sj.bmt.1705026", "volume": "36", "author": "F Ratjen", "year": "2005", "unstructured": "Ratjen F, Rjabko O, Kremens B . High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant 2005; 36: 135\u2013138.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFbmt2012228_CR10", "doi-asserted-by": "publisher", "first-page": "334", "DOI": "10.1016/j.bbmt.2012.01.003", "volume": "18", "author": "MA Pulsipher", "year": "2012", "unstructured": "Pulsipher MA, Skinner R, McDonald GB, Hingorani S, Armenian SH, Cooke KR et al. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines. Biol Blood Marrow Transplant 2012; 18: 334\u2013347.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt2012228_CR11", "doi-asserted-by": "publisher", "first-page": "327", "DOI": "10.1097/00005792-198709000-00001", "volume": "66", "author": "CK Chan", "year": "1987", "unstructured": "Chan CK, Hyland RH, Hutcheon MA, Minden MD, Alexander MA, Kossakowska AE et al. Small-airways disease in recipients of allogeneic bone marrow transplants. An analysis of 11 cases and a review of the literature. Medicine (Baltimore) 1987; 66: 327\u2013340.", "journal-title": "Medicine (Baltimore)"}, {"key": "BFbmt2012228_CR12", "doi-asserted-by": "crossref", "first-page": "945", "DOI": "10.1016/j.bbmt.2005.09.004", "volume": "11", "author": "AH Filipovich", "year": "2005", "unstructured": "Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt2012228_CR13", "doi-asserted-by": "publisher", "first-page": "365", "DOI": "10.1378/chest.113.2.365", "volume": "113", "author": "AN Leung", "year": "1998", "unstructured": "Leung AN, Fisher K, Valentine V, Girgis RE, Berry GJ, Robbins RC et al. Bronchiolitis obliterans after lung transplantation: detection using expiratory HRCT. Chest 1998; 113: 365\u2013370.", "journal-title": "Chest"}, {"key": "BFbmt2012228_CR14", "doi-asserted-by": "publisher", "first-page": "1072", "DOI": "10.1016/j.bbmt.2010.11.018", "volume": "17", "author": "BK Au", "year": "2011", "unstructured": "Au BK, Au MA, Chien JW . Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1072\u20131078.", "journal-title": "Biol Blood Marrow Transplant"}, {"key": "BFbmt2012228_CR15", "doi-asserted-by": "publisher", "first-page": "1068", "DOI": "10.1136/thx.2004.022590", "volume": "59", "author": "P Aurora", "year": "2004", "unstructured": "Aurora P, Gustafsson P, Bush A, Lindblad A, Oliver C, Wallis CE et al. Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. Thorax 2004; 59: 1068\u20131073.", "journal-title": "Thorax"}, {"key": "BFbmt2012228_CR16", "doi-asserted-by": "publisher", "first-page": "249", "DOI": "10.1164/rccm.200407-895OC", "volume": "171", "author": "P Aurora", "year": "2005", "unstructured": "Aurora P, Bush A, Gustafsson P, Oliver C, Wallis C, Price J et al. London Cystic Fibrosis Collaboration. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. Am J Respir Crit Care Med 2005; 171: 249\u2013256.", "journal-title": "Am J Respir Crit Care Med"}, {"key": "BFbmt2012228_CR17", "first-page": "782", "volume": "16", "author": "AB Versluys", "year": "2010", "unstructured": "Versluys AB, Rossen JW, van Ewijk B, Schuurman R, Bierings MB . Boelens JJBiol Blood Marrow Transplant. Strong association between respiratory viral infection early after hematopoietic stem cell transplantation and the development of life-threatening acute and chronic alloimmune lung syndromes 2010; 16: 782\u2013791.", "journal-title": "Strong association between respiratory viral infection early after hematopoietic stem cell transplantation and the development of life-threatening acute and chronic alloimmune lung syndromes"}, {"key": "BFbmt2012228_CR18", "doi-asserted-by": "publisher", "first-page": "2277", "DOI": "10.1056/NEJMra072149", "volume": "357", "author": "DJ Brenner", "year": "2007", "unstructured": "Brenner DJ, Hall EJ . Computed tomography\u2013an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277\u20132284.", "journal-title": "N Engl J Med"}], "container-title": ["Bone Marrow Transplantation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/bmt2012228.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt2012228", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/bmt2012228.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 13]], "date-time": "2019-04-13T14:09:07Z", "timestamp": 1555164547000}, "score": 23.658169, "issued": {"date-parts": [[2012, 11, 19]]}, "references-count": 18, "journal-issue": {"published-print": {"date-parts": [[2013, 6]]}, "issue": "6"}, "alternative-id": ["BFbmt2012228"], "URL": "http://dx.doi.org/10.1038/bmt.2012.228", "relation": {"cites": []}, "ISSN": ["0268-3369", "1476-5365"], "issn-type": [{"value": "0268-3369", "type": "print"}, {"value": "1476-5365", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T18:25:01Z", "timestamp": 1574101501231}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1997, 7, 1]], "date-time": "1997-07-01T00:00:00Z", "timestamp": 867715200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1997, 7]]}, "DOI": "10.1016/s0013-4694(97)88999-0", "type": "journal-article", "created": {"date-parts": [[2002, 7, 25]], "date-time": "2002-07-25T19:08:57Z", "timestamp": 1027624137000}, "page": "208", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Neurophysiological classification of carpal tunnel syndrome: Clinical and prognostic value"], "prefix": "10.1016", "volume": "103", "author": [{"given": "L", "family": "Padua", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Electroencephalography and Clinical Neurophysiology"], "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0013-4694(97)88999-0?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0013-4694(97)88999-0?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 23]], "date-time": "2019-04-23T00:27:18Z", "timestamp": 1555979238000}, "score": 23.638746, "issued": {"date-parts": [[1997, 7]]}, "references-count": 0, "journal-issue": {"issue": "1"}, "alternative-id": ["S0013-4694(97)88999-0"], "URL": "http://dx.doi.org/10.1016/s0013-4694(97)88999-0", "ISSN": ["0013-4694"], "issn-type": [{"value": "0013-4694", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T16:02:20Z", "timestamp": 1574524940915}, "reference-count": 0, "publisher": "Ferrata Storti Foundation (Haematologica)", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Haematologica"], "published-print": {"date-parts": [[2013, 1, 1]]}, "DOI": "10.3324/haematol.2012.069385", "type": "journal-article", "created": {"date-parts": [[2012, 12, 31]], "date-time": "2012-12-31T23:25:31Z", "timestamp": 1356996331000}, "page": "10-22", "source": "Crossref", "is-referenced-by-count": 14, "title": ["Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?"], "prefix": "10.3324", "volume": "98", "author": [{"given": "S.", "family": "Beurlet", "sequence": "first", "affiliation": []}, {"given": "C.", "family": "Chomienne", "sequence": "additional", "affiliation": []}, {"given": "R. A.", "family": "Padua", "sequence": "additional", "affiliation": []}], "member": "1856", "published-online": {"date-parts": [[2012, 10, 12]]}, "container-title": ["Haematologica"], "language": "en", "deposited": {"date-parts": [[2013, 1, 16]], "date-time": "2013-01-16T23:39:05Z", "timestamp": 1358379545000}, "score": 23.562672, "issued": {"date-parts": [[2012, 10, 12]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2012, 12, 31]]}, "published-print": {"date-parts": [[2013, 1, 1]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.3324/haematol.2012.069385", "ISSN": ["0390-6078", "1592-8721"], "issn-type": [{"value": "0390-6078", "type": "print"}, {"value": "1592-8721", "type": "electronic"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}